U.S. patent application number 17/471914 was filed with the patent office on 2021-12-30 for salivary extracellular rna biomarkers for gingivitis.
This patent application is currently assigned to Colgate-Palmolive Company. The applicant listed for this patent is Colgate-Palmolive Company, The Regents of the University of California. Invention is credited to Karolina Elzbieta KACZOR-URBANOWICZ, James MASTERS, Harsh Mahendra TRIVEDI, David T.W. WONG.
Application Number | 20210404006 17/471914 |
Document ID | / |
Family ID | 1000005836420 |
Filed Date | 2021-12-30 |
United States Patent
Application |
20210404006 |
Kind Code |
A1 |
WONG; David T.W. ; et
al. |
December 30, 2021 |
Salivary Extracellular Rna Biomarkers for Gingivitis
Abstract
Described herein are methods used for the detection of
gingivitis and the monitoring of gingivitis in a subject.
Inventors: |
WONG; David T.W.; (Beverly
Hills, CA) ; KACZOR-URBANOWICZ; Karolina Elzbieta;
(Los Angeles, CA) ; TRIVEDI; Harsh Mahendra;
(Hillsborough, NJ) ; MASTERS; James; (Ringoes,
NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Colgate-Palmolive Company
The Regents of the University of California |
New York
Oakland |
NY
CA |
US
US |
|
|
Assignee: |
Colgate-Palmolive Company
New York
NY
The Regents of the University of California
Oakland
CA
|
Family ID: |
1000005836420 |
Appl. No.: |
17/471914 |
Filed: |
September 10, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16171418 |
Oct 26, 2018 |
11124833 |
|
|
17471914 |
|
|
|
|
62577887 |
Oct 27, 2017 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12Q 2600/158 20130101;
C12Q 2600/106 20130101; C12Q 2600/178 20130101; C12Q 1/6883
20130101 |
International
Class: |
C12Q 1/6883 20060101
C12Q001/6883 |
Claims
1-16. (canceled)
17. A kit for detecting of gingivitis comprising a reagent that
detects the presence of at least one biomarker selected from the
group consisting of NONHSAT006501.2, NONHSAT071649, NONHSAT005224,
LGALS3, AF156166, SOX4, FAM25A, AL832615, SLPI, and CRCT1 in a
saliva sample.
18. (canceled)
19. The kit of claim 17, comprising one or more of a protease
inhibitor, a RNase inhibitor, and a DNase.
20. The kit of claim 17, comprising one or more of a reverse
transcriptase and a primer.
21. The kit of claim 17, comprising one or more of a
deoxyribonucleoside and a ribonucleoside.
22. The kit of claim 17, comprising one or more reagent used for
reverse transcription quantitative real-time PCR.
23. The kit of claim 17, comprising one or more reagents for
amplification of said one or more biomarkers.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority from U.S.
Provisional Application No. 62/577,877, filed Oct. 27, 2017, the
contents of which are hereby incorporated herein by reference in
their entirety.
BACKGROUND
[0002] Periodontal diseases are the most common inflammatory
disease affecting up to 90% of the population worldwide (Pihlstrom
et al., 2005, Lancet, 366, 1809-20). Gingivitis, the reversible
form of the disease, is induced by the accumulation of bacterial
biofilm, and comprises the majority of the cases of patients with
periodontal diseases (>75%) (Albandar et al., 1999, J
Periodontol 70, 30-43; Tomar et al., 2000, J Periodontol., 71,
743-751). If left untreated, gingivitis may progress to
periodontitis, which involves bone and attachment loss and it is
mostly irreversible. Periodontitis can advance to the point that it
induces tooth mobility and tooth loss. It may also adversely affect
systemic health via ischemic stroke, cardiovascular events or
cancers (Binder et al., 2015, Oncotarget 6, 22613-23; Mitsuhashi et
al., 2015, Oncotarget, 6, 7209-7220). The common risk factors for
periodontitis could be divided into inherited (e.g., genetic
variants), and those that are acquired (e.g., socio-economic
factors, poor oral hygiene, cigarette smoking and diabetes)
(Chapple et al., 2017, Journal of Clinical Periodontology, 44
(Suppl 18), S39-S51).
[0003] The quest to develop salivary biomarkers for periodontal
diseases has been elusive (Giannobile et al., 2009, Periodontol
2000, 50, 52-64). Despite the scientific acceptance of salivary
biomarkers for the detection of gingivitis (Henskens et al., 2003,
J Periodontal Res., 28, 43-48; Kinney et al., 2011, J. Dent. Res.,
90, 752-8; Lee et al., 2012, J Periodontol., 83, 79-89; Shaila et
al., 2013; J Indian Soc Periodontol., 17, 42-46; Morelli et al.,
2014, J Periodontol., 85, 1770-8), the absence of definitively
validated biomarkers prevents the regulatory approval and
translation of a diagnostic test into clinical practice. Presently,
the gold standard for early detection and diagnosis for gingivitis
mainly includes a comprehensive periodontal exam along with
subjective visual inspection (i.e. redness, swelling or gingival
bleeding) performed during dental examinations. Bleeding upon
probing, confirms the presence of gingivitis. Unfortunately, the
absence of pain in gingivitis often renders individuals unaware of
their pathologic gingival condition, particularly if they do not
have to visit the dentist regularly. Thus, it is desirable to
develop objective and scientifically credible biomarkers for early
detection and monitoring of gingivitis as many of the gingivitis
cases are left untreated (Albandar et al., 1999, J Periodontol 70,
30-43; Tomar et al., 2000, J Periodontol., 71, 743-751).
[0004] Thus, there is a need in the art for improved compositions
and methods for detecting gingivitis. The present invention
satisfies this unmet need.
BRIEF SUMMARY
[0005] In one aspect, the present invention provides a method of
diagnosing gingivitis in a subject. The method comprises detecting
the level of at least one biomarker in a saliva sample of the
subject, wherein the at least one biomarker is selected from the
group consisting of NONHSAT006501.2, NONHSAT071649, NONHSAT005224,
LGALS3, AF156166, SOX4, FAM25A, AL832615, SLPI, and CRCT1;
detecting that the level of the at least one biomarker in the
saliva sample of the subject is differentially expressed as
compared to the level of the at least one biomarker in a comparator
control, and detecting gingivitis in the subject when the level of
the at least one biomarker in the saliva sample of subject is
differentially expressed when compared with the level of the
biomarker in the comparator control. In one embodiment, the
comparator control is the level of the at least one biomarker in
the saliva sample of a subject or population not having gingivitis.
In one embodiment, the method comprises the further step of
treating the subject for gingivitis.
[0006] In one embodiment, the method comprises detecting that the
level of at least one biomarker selected from the group consisting
of NONHSAT071649, NONHSAT005224, AF156166, and SOX4 is increased as
compared to the level of the at least one biomarker in the
comparator control. In on embodiment, the method comprises
detecting that the level of at least one biomarker selected from
the group consisting of NONHSAT006501.2, LGALS3, FAM25A, and CRCT1
is decreased as compared to the level of the at least one biomarker
in the comparator control.
[0007] In one embodiment, the level of the at least one biomarker
in the saliva sample is determined by measuring the level of mRNA
of the at least one biomarker in the saliva sample. In one
embodiment, the level of the at least one biomarker in the saliva
sample is determined by measuring the level of polypeptide of the
at least one biomarker in the saliva sample.
[0008] In one embodiment, the comparator control is at least one
selected from the group consisting of a positive control, a
negative control, a historical control, a historical norm, or the
level of a reference molecule in the biological sample. In one
embodiment, the subject is human.
[0009] In one aspect, the present invention provides a method of
monitoring the response to a gingivitis treatment in a subject. The
method comprises detecting the level of at least one biomarker in a
saliva sample of the subject obtained after the treatment is
initiated, wherein the at least one biomarker is selected from the
group consisting of NONHSAT006501.2, NONHSAT071649, NONHSAT005224,
LGALS3, AF156166, SOX4, FAM25A, AL832615, SLPI, and CRCT1;
detecting that the level of the at least one biomarker in the
saliva sample of the subject is differentially expressed as
compared to the level of the at least one biomarker in a comparator
control, and detecting that the subject is responsive to the
treatment when the level of the at least one biomarker in the
saliva sample of subject is differentially expressed when compared
with the level of the biomarker of the comparator control. In one
embodiment, the comparator control a saliva sample of the subject
obtained prior to initiation of the treatment. In one embodiment,
the comparator control comprises a saliva sample of the subject
obtained at an earlier time point during the treatment.
[0010] In one aspect, the present invention provides a method
comprising obtaining a saliva sample of a subject; and detecting
the level of at least one biomarker in a saliva sample of the
subject, wherein the at least one biomarker is selected from the
group consisting of NONHSAT006501.2, NONHSAT071649, NONHSAT005224,
LGALS3, AF156166, SOX4, FAM25A, AL832615, SLPI, and CRCT1. In one
embodiment, the level of the at least one biomarker in the saliva
sample is determined by measuring the level of mRNA of the at least
one biomarker in the saliva sample. In one embodiment, the level of
the at least one biomarker in the saliva sample is determined by
measuring the level of polypeptide of the at least one biomarker in
the saliva sample.
[0011] In one aspect, the present invention provides a method of
treating gingivitis, comprising administering a gingivitis
treatment to a subject identified as having a differential level of
at least one biomarker selected from the group consisting of
NONHSAT006501.2, NONHSAT071649, NONHSAT005224, LGALS3, AF156166,
SOX4, FAM25A, AL832615, SLPI, and CRCT1 in a saliva sample of the
subject.
[0012] In one aspect, the present invention provides a kit for
detecting of gingivitis comprising a reagent that detects the
presence of at least one biomarker selected from the group
consisting of NONHSAT006501.2, NONHSAT071649, NONHSAT005224,
LGALS3, AF156166, SOX4, FAM25A, AL832615, SLPI, and CRCT1 in a
saliva sample.
[0013] In one aspect, the present invention provides a method of
treating gingivitis in a subject, comprising detecting the level of
at least one biomarker in a saliva sample of the subject, wherein
the at least one biomarker is selected from the group consisting of
NONHSAT006501.2, NONHSAT071649, NONHSAT005224, LGALS3, AF156166,
SOX4, FAM25A, AL832615, SLPI, and CRCT1; detecting that the level
of the at least one biomarker in the saliva sample of the subject
is differentially expressed as compared to the level of the at
least one biomarker in a comparator control, detecting gingivitis
in the subject when the level of the at least one biomarker in the
saliva sample of subject is differentially expressed when compared
with the level of the biomarker in the comparator control; and
administering a gingivitis treatment to the subject.
BRIEF DESCRIPTION OF THE DRAWINGS
[0014] The following detailed description of embodiments of the
invention will be better understood when read in conjunction with
the appended drawings. It should be understood that the invention
is not limited to the precise arrangements and instrumentalities of
the embodiments shown in the drawings.
[0015] FIG. 1 depicts the results of example experiments depicting
the top 25 salivary exRNA biomarker candidates (Affymetrix HTA 2.0
microarray analysis).
[0016] FIG. 2 depicts the results of example experiments depicting
the concordance of 10 salivary exRNA biomarker changes with initial
microarray data.
[0017] FIG. 3 depicts the results of example experiments depicting
the validation of HTA 2.0 Affymetrix array profiling results by
qRT-PCR. The list of 10 exRNAs with fold changes and p-values. A
plot presenting the fold changes and 95% confidence interval (CI)
for each of 10 salivary exRNA biomarkers on the log base 2 scale
for the baseline-week 6 period.
[0018] FIG. 4 depicts the results of example experiments
demonstrating the performance of salivary exRNA biomarkers to
classify gingivitis from healthy subjects with no periodontal
disease [baseline to 6 weeks], [4 exRNAs: NONHSAT006501.2 (m1);
NONHSAT071649 (m2), NM_001146157 (m7), NM_019060 (m10)] [0.91 AUC,
71% sensitivity, 100% specificity].
[0019] FIG. 5 depicts a summary of demographic and clinical data
for the subjects included in the validation phase.
[0020] FIG. 6 depicts the results of example experiments
demonstrating a comparison of the Gingival Index and the Plaque
Index scores over time.
[0021] FIG. 7 depicts the results of example experiments
demonstrating a comparison of biomarker expression levels of 8
validated salivary exRNAs at each time point and longitudinally
(normalized .DELTA.Ct values according to reference gene ACTB).
P-values are represented for each marker over time [Baseline-week 3
(B-3) & Baseline-week 6 (B-6)]. The graph presents
statistically significant overall trends, increasing or decreasing,
for each marker across all 3 time points (baseline, week 3 &
week 6).
[0022] FIG. 8 depicts the results of example experiments of a
clinical evaluator investigation over time (at screening, baseline,
3 and 6 weeks).
DETAILED DESCRIPTION
[0023] The present invention provides methods to detect and measure
saliva-based biomarkers for the detection of gingivitis in a
subject. For example, in some embodiments, the biomarkers described
herein can be used to assess the status of gingivitis, monitor
gingivitis regression or monitor a response to gingivitis
treatment. The markers of the invention can be used to screen,
assess risk, diagnose and monitor gingivitis. The detection or
diagnosis of gingivitis in a subject using the markers of the
invention can be used to establish and evaluate treatment plans for
gingivitis.
[0024] The present invention therefore provides compositions and
methods of diagnosing and providing a prognosis for gingivitis, by
examining relevant biomarkers and their expression. In one
embodiment, biomarker expression includes transcription into
messenger RNA (mRNA) and translation into protein, as well as
transcription into types of RNA such as long non-coding RNA
(lncRNA), transfer RNA (tRNA) and ribosomal RNA (rRNA) that are not
translated into protein.
[0025] In one embodiment, the biomarkers for the detection of
gingivitis or for monitoring of gingivitis regression or response
to treatment includes but are not limited to the biomarkers
provided in FIG. 1 or FIG. 2, including but not limited to SPRR1A,
FAM25C, CNFN, S100A12, FAM25A, CRCT1, ANXA1, MUC21, LCE3E, SRRM5,
AC073046.25, SLPI, KRT4, LGALS3, CCL4L1, OR1L3, SOX4, RP5-965F6.2,
PET100, NONHSAT006501.2, NONHSAT071649, NONHSAT005224, AF156166,
and AL832615.
[0026] In one embodiment, the biomarkers includes one or more
lncRNAs selected from the group consisting of NONHSAT006501.2,
NONHSAT071649, and NONHSAT005224. In one embodiment, the biomarkers
includes one or more mRNAs selected from the group consisting of
LGALS3, AF156166, SOX4, FAM25A, AL832615, SLPI, and CRCT1.
[0027] In some embodiments, the biomarkers described herein are
extracellular biomarkers. For example, in some embodiments, the
biomarkers described herein are extracellular biomarkers detected
in saliva supernatant.
[0028] In some embodiments, the biomarkers are used in conjunction
with one or more subject characteristics to detect or diagnose
gingivitis. For example, the subject characteristics include, but
is not limited to, gender, age, ethnicity, height, weight, diet,
genetics, smoking, mouth-breathing, mouth-breathing during sleep,
obesity, heart disease, osteoporosis, hypertension, diabetes, bowel
diseases, muscle and joint disease, tumor, mental illness, caries,
missing teeth, level of oral hygiene, level of dental care
utilization, and use of medications that dry the mouth.
[0029] In some embodiments, the biomarkers are used in conjunction
with one or more assays for gingivitis, including, but not limited
to Loe-Silness Gingival Index (GI), Quigley and Hein Plaque Index
(PI), Turesky-modification of the Quigly and Hein index, gingival
bleeding index, Navy index, modified Navy index, bleeding on
probing (BOP), and probing depth (PD).
[0030] Accordingly, in some embodiments of the invention, methods
for diagnosing gingivitis is provided. The methods comprise a)
providing a saliva sample from the subject; b) analyzing the saliva
sample with an assay that specifically detects at least one
biomarker of the invention in the saliva sample; c) comparing the
subject biomarker profile with a control biomarker profile wherein
a statistically significant difference between the subject
biomarker profile and the control biomarker profile is indicative
of gingivitis. In some embodiments, the methods further comprise
the step of d) effectuating a treatment regimen based thereon.
[0031] In one embodiment, the biomarker types comprise RNA
biomarkers. In various embodiments, the RNA is detected by at least
one of mass spectroscopy, PCR microarray, thermal sequencing,
capillary array sequencing, solid phase sequencing, and the
like.
[0032] In another embodiment, the biomarker types comprise
polypeptide biomarkers. In various embodiments, the polypeptide is
detected by at least one of ELISA, Western blot, flow cytometry,
immunofluorescence, immunohistochemistry, mass spectroscopy, and
the like.
Definitions
[0033] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. Any
methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the present
invention.
[0034] As used herein, the words "preferred" and "preferably" refer
to embodiments of the invention that afford certain benefits, under
certain circumstances. However, other embodiments may also be
preferred, under the same or other circumstances. Furthermore, the
recitation of one or more preferred embodiments does not imply that
other embodiments are not useful, and is not intended to exclude
other embodiments from the scope of the invention.
[0035] Unless stated otherwise, all percentages of composition
components given in this specification are by weight based on a
total composition or formulation weight of 100%.
[0036] As used herein, each of the following terms has the meaning
associated with it in this section.
[0037] The articles "a" and "an" are used herein to refer to one or
to more than one (i.e., to at least one) of the grammatical object
of the article. By way of example, "an element" means one element
or more than one element.
[0038] "About" as used herein when referring to a measurable value
such as an amount, a temporal duration, and the like, is meant to
encompass variations of .+-.20%, .+-.10%, .+-.5%, .+-.1%, or
.+-.0.1% from the specified value, as such variations are
appropriate to perform the disclosed methods.
[0039] The term "abnormal" when used in the context of organisms,
tissues, cells or components thereof, refers to those organisms,
tissues, cells or components thereof that differ in at least one
observable or detectable characteristic (e.g., age, treatment, time
of day, etc.) from those organisms, tissues, cells or components
thereof that display the "normal" (expected) respective
characteristic. Characteristics which are normal or expected for
one cell or tissue type, might be abnormal for a different cell or
tissue type.
[0040] As used herein the terms "alteration," "defect,"
"variation," or "mutation," refers to a mutation in a gene in a
cell that affects the function, activity, expression (transcription
or translation) or conformation of the polypeptide that it encodes.
Mutations encompassed by the present invention can be any mutation
of a gene in a cell that results in the enhancement or disruption
of the function, activity, expression or conformation of the
encoded polypeptide, including the complete absence of expression
of the encoded protein and can include, for example, missense and
nonsense mutations, insertions, deletions, frameshifts and
premature terminations. Without being so limited, mutations
encompassed by the present invention may alter splicing the mRNA
(splice site mutation) or cause a shift in the reading frame
(frameshift).
[0041] The term "amplification" refers to the operation by which
the number of copies of a target nucleotide sequence present in a
sample is multiplied.
[0042] By the term "applicator," as the term is used herein, is
meant any device including, but not limited to, a hypodermic
syringe, a pipette, an iontophoresis device, a patch, and the like,
for administering the compositions of the invention to a
subject.
[0043] The term "antibody," as used herein, refers to an
immunoglobulin molecule which specifically binds with an antigen.
Antibodies can be intact immunoglobulins derived from natural
sources or from recombinant sources and can be immunoreactive
portions of intact immunoglobulins. Antibodies are typically
tetramers of immunoglobulin molecules. The antibodies in the
present invention may exist in a variety of forms including, for
example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and
F(ab).sub.2, as well as single chain antibodies and humanized
antibodies (Harlow et al., 1999, In: Using Antibodies: A Laboratory
Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al.,
1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor,
N.Y.; Houston et al., 1988, Proc. Natl. Acad. Sci. USA
85:5879-5883; Bird et al., 1988, Science 242:423-426).
[0044] An "antibody heavy chain," as used herein, refers to the
larger of the two types of polypeptide chains present in all
antibody molecules in their naturally occurring conformations.
[0045] An "antibody light chain," as used herein, refers to the
smaller of the two types of polypeptide chains present in all
antibody molecules in their naturally occurring conformations.
.kappa. and .lamda. light chains refer to the two major antibody
light chain isotypes.
[0046] By the term "synthetic antibody" as used herein, is meant an
antibody which is generated using recombinant DNA technology, such
as, for example, an antibody expressed by a bacteriophage as
described herein. The term should also be construed to mean an
antibody which has been generated by the synthesis of a DNA
molecule encoding the antibody and which DNA molecule expresses an
antibody protein, or an amino acid sequence specifying the
antibody, wherein the DNA or amino acid sequence has been obtained
using synthetic DNA or amino acid sequence technology which is
available and well known in the art.
[0047] By the term "specifically binds," as used herein with
respect to an antibody, is meant an antibody which recognizes a
specific antigen, but does not substantially recognize or bind
other molecules in a sample. For example, an antibody that
specifically binds to an antigen from one species may also bind to
that antigen from one or more species. But, such cross-species
reactivity does not itself alter the classification of an antibody
as specific. In another example, an antibody that specifically
binds to an antigen may also bind to different allelic forms of the
antigen. However, such cross reactivity does not itself alter the
classification of an antibody as specific. In some instances, the
terms "specific binding" or "specifically binding," can be used in
reference to the interaction of an antibody, a protein, or a
peptide with a second chemical species, to mean that the
interaction is dependent upon the presence of a particular
structure (e.g., an antigenic determinant or epitope) on the
chemical species; for example, an antibody recognizes and binds to
a specific protein structure rather than to proteins generally. If
an antibody is specific for epitope "A", the presence of a molecule
containing epitope A (or free, unlabeled A), in a reaction
containing labeled "A" and the antibody, will reduce the amount of
labeled A bound to the antibody.
[0048] As used herein, the term "marker" or "biomarker" is meant to
include a parameter (e.g., RNA, polypeptide, etc.) which is useful
according to this invention for determining the presence and/or
severity and/or stage of gingivitis.
[0049] The level of a marker or biomarker "significantly" differs
from the level of the marker or biomarker in a reference sample or
comparator if the level of the marker in a sample from the patient
differs from the level in a reference sample or comparator by an
amount greater than the standard error of the assay employed to
assess the marker, for example at least 10%, 25%, 50%, 75%, or
100%.
[0050] The term "control or reference standard or comparator"
describes a material comprising none, or a normal, low, or high
level of one of more of the marker (or biomarker) expression
products of one or more the markers (or biomarkers) of the
invention, such that the control or reference standard or
comparator may serve as a comparator against which a sample can be
compared.
[0051] By the phrase "determining the level of marker (or
biomarker) expression" is meant an assessment of the degree of
expression of a marker in a sample at the nucleic acid or protein
level, using technology available to the skilled artisan to detect
a sufficient portion of any marker expression product.
[0052] "Differentially increased expression" or "up regulation"
refers to biomarker product levels which are increased by at least
10% or more, for example, 20%, 30%, 40%, or 50%, 60%, 70%, 80%, 90%
or more, and/or 1.1 fold, 1.2 fold, 1.4 fold, 1.6 fold, 1.8 fold,
2.0 fold or more, and any and all whole or partial increments
therebetween than a control.
[0053] "Differentially decreased expression" or "down regulation"
refers to biomarker product levels which are reduced or decreased
by at least 10% or more, for example, 20%, 30%, 40%, or 50%, 60%,
70%, 80%, 90% or more, and/or 2.0 fold, 1.8 fold, 1.6 fold, 1.4
fold, 1.2 fold, 1.1 fold or more, and any and all whole or partial
increments therebetween than a control.
[0054] A "disease" is a state of health of an animal wherein the
subject cannot maintain homeostasis, and wherein if the disease is
not ameliorated then the subject's health continues to
deteriorate.
[0055] As used herein, an "immunoassay" refers to a biochemical
test that measures the presence or concentration of a substance in
a sample, such as a biological sample, using the reaction of an
antibody to its cognate antigen, for example the specific binding
of an antibody to a protein. Both the presence of the antigen or
the amount of the antigen present can be measured.
[0056] As used herein, an "instructional material" includes a
publication, a recording, a diagram, or any other medium of
expression which can be used to communicate the usefulness of a
component of the invention in a kit for detecting biomarkers
disclosed herein. The instructional material of the kit of the
invention can, for example, be affixed to a container which
contains the component of the invention or be shipped together with
a container which contains the component. Alternatively, the
instructional material can be shipped separately from the container
with the intention that the instructional material and the
component be used cooperatively by the recipient.
[0057] The term "label" when used herein refers to a detectable
compound or composition that is conjugated directly or indirectly
to a probe to generate a "labeled" probe. The label may be
detectable by itself (e.g., radioisotope labels or fluorescent
labels) or, in the case of an enzymatic label, may catalyze
chemical alteration of a substrate compound or composition that is
detectable (e.g., avidin-biotin). In some instances, primers can be
labeled to detect a PCR product.
[0058] The "level" of one or more biomarkers means the absolute
amount or relative amount or concentration of the biomarker in the
sample.
[0059] The term "marker (or biomarker) expression" as used herein,
encompasses the transcription, translation, post-translation
modification, and phenotypic manifestation of a gene, including all
aspects of the transformation of information encoded in a gene into
RNA or protein. By way of non-limiting example, marker expression
includes transcription into messenger RNA (mRNA) and translation
into protein, as well as transcription into types of RNA such as
transfer RNA (tRNA) and ribosomal RNA (rRNA) that are not
translated into protein.
[0060] The terms "microarray" and "array" refers broadly to both
"DNA microarrays" and "DNA chip(s)," and encompasses all
art-recognized solid supports, and all art-recognized methods for
affixing nucleic acid molecules thereto or for synthesis of nucleic
acids thereon. In some instances, arrays comprise a plurality of
different nucleic acid probes that are coupled to a surface of a
substrate in different, known locations. These arrays, also
described as "microarrays" or colloquially "chips" have been
generally described in the art, for example, U.S. Pat. Nos.
5,143,854, 5,445,934, 5,744,305, 5,677,195, 5,800,992, 6,040,193,
5,424,186 and Fodor et al., 1991, Science, 251:767-777, each of
which is incorporated by reference in its entirety for all
purposes. Arrays may generally be produced using a variety of
techniques, such as mechanical synthesis methods or light directed
synthesis methods that incorporate a combination of
photolithographic methods and solid phase synthesis methods.
Techniques for the synthesis of these arrays using mechanical
synthesis methods are described in, e.g., U.S. Pat. Nos. 5,384,261,
and 6,040,193, which are incorporated herein by reference in their
entirety for all purposes. In one embodiment, the array is a planar
array surface. In some embodiments, the array is fabricated on a
surface of virtually any shape or even a multiplicity of surfaces.
Arrays may be nucleic acids on beads, gels, polymeric surfaces,
fibers such as fiber optics, glass or any other appropriate
substrate. (See U.S. Pat. Nos. 5,770,358, 5,789,162, 5,708,153,
6,040,193 and 5,800,992, which are hereby incorporated by reference
in their entirety for all purposes.) Arrays may be packaged in such
a manner as to allow for diagnostic use or can be an all-inclusive
device; e.g., U.S. Pat. Nos. 5,856,174 and 5,922,591 incorporated
in their entirety by reference for all purposes. Arrays are
commercially available from, for example, Affymetrix (Santa Clara,
Calif.) and Applied Biosystems (Foster City, Calif.), and are
directed to a variety of purposes, including genotyping,
diagnostics, mutation analysis, marker expression, and gene
expression monitoring for a variety of eukaryotic and prokaryotic
organisms. The number of probes on a solid support may be varied by
changing the size of the individual features. In one embodiment the
feature size is 20 by 25 microns square, in other embodiments
features may be, for example, 8 by 8, 5 by 5 or 3 by 3 microns
square, resulting in about 2,600,000, 6,600,000 or 18,000,000
individual probe features.
[0061] "Measuring" or "measurement," or alternatively "detecting"
or "detection," means assessing the presence, absence, quantity or
amount (which can be an effective amount) of either a given
substance within a clinical or subject-derived sample, including
the derivation of qualitative or quantitative concentration levels
of such substances, or otherwise evaluating the values or
categorization of a subject's clinical parameters.
[0062] By the term "modulating," as used herein, is meant mediating
a detectable increase or decrease in the activity and/or level of a
mRNA, polypeptide, or a response in a subject compared with the
activity and/or level of a mRNA, polypeptide or a response in the
subject in the absence of a treatment or compound, and/or compared
with the activity and/or level of a mRNA, polypeptide, or a
response in an otherwise identical but untreated subject.
[0063] A "normal" subject does not have a clinical manfestation of
gingivitis. In some instances a "normal" subject has a depth of
gingival pocket of less than about 3 mm.
[0064] The terms "patient," "subject," "individual," and the like
are used interchangeably herein, and refer to any animal, or cells
thereof whether in vitro or in situ, amenable to the methods
described herein. In some non-limiting embodiments, the patient,
subject or individual is a human.
[0065] As used herein, the term "providing a prognosis" refers to
providing a prediction of the probable course and outcome of
diabetes, including prediction of severity, duration, chances of
recovery, etc. The methods can also be used to devise a suitable
therapeutic plan, e.g., by indicating whether or not the condition
is still at an early stage or if the condition has advanced to a
stage where aggressive therapy would be ineffective.
[0066] A "reference level" of a biomarker means a level of the
biomarker that is indicative of a particular disease state,
phenotype, or lack thereof, as well as combinations of disease
states, phenotypes, or lack thereof. A "positive" reference level
of a biomarker means a level that is indicative of a particular
disease state or phenotype. A "negative" reference level of a
biomarker means a level that is indicative of a lack of a
particular disease state or phenotype.
[0067] The term "risk stratification," according to the invention,
comprises finding patients for the purpose of diagnosis and
therapy/treatment (of sequelae) of gingivitis, with the goal of
allowing as advantageous a course of the gingivitis as
possible.
[0068] "Sample" or "biological sample" as used herein means a
biological material isolated from an individual. The biological
sample may contain any biological material suitable for detecting
the desired biomarkers, and may comprise cellular and/or
non-cellular material obtained from the individual. One example of
a biological sample is a whole saliva sample. Another example of a
biological sample is a cell-free saliva sample.
[0069] Another example of a biological sample is a saliva
supernatant, such as the supernatant obtained after centrifuging a
saliva sample. Another example of a biological sample is the
material in a pellet obtained from a saliva sample, such as a
pellet obtained after centrifuging a saliva sample (i.e., saliva
pellet).
[0070] "Standard control value" as used herein refers to a
predetermined amount of a particular protein or nucleic acid that
is detectable in a saliva sample, either in whole saliva or in a
saliva pellet or in a saliva supernatant. The standard control
value is suitable for the use of a method of the present invention,
in order for comparing the amount of a protein or nucleic acid of
interest (e.g., marker, biomarker) that is present in a saliva
sample. An established sample serving as a standard control
provides an typical amount of the protein or nucleic acid of
interest in the saliva that is typical for an typical, healthy
person of reasonably matched background, e.g., gender, age,
ethnicity, and medical history. A standard control value may vary
depending on the protein or nucleic acid of interest and the nature
of the sample (e.g., whole saliva, saliva supernatant, etc.).
[0071] Ranges: throughout this disclosure, various aspects of the
invention can be presented in a range format. It should be
understood that the description in range format is merely for
convenience and brevity and should not be construed as an
inflexible limitation on the scope of the invention. Accordingly,
the description of a range should be considered to have
specifically disclosed all the possible subranges as well as
individual numerical values within that range. For example,
description of a range such as from 1 to 6 should be considered to
have specifically disclosed subranges such as from 1 to 3, from 1
to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as
well as individual numbers within that range, for example, 1, 2,
2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of
the range.
DESCRIPTION
[0072] The present invention is based on the identification of
extracellular biomarkers present in or absent from a saliva
supernatant sample that can identify a subject as having
gingivitis, monitor gingivitis regression in a subject, and monitor
a response to gingivitis treatment in a subject.
[0073] In one embodiment, the invention provides a biomarker for
the detection of gingivitis. In one embodiment, the biomarkers
includes one or more lncRNAs selected from the group consisting of
NONHSAT006501.2, NONHSAT071649, and NONHSAT005224. In one
embodiment, the biomarkers includes one or more mRNAs selected from
the group consisting of LGALS3, AF156166, SOX4, FAM25A, AL832615,
SLPI, and CRCT1.
[0074] In one embodiment, the invention provides a method of
detecting or diagnosing gingivitis in a subject, comprising
measuring the level of at least one of NONHSAT006501.2,
NONHSAT071649, NONHSAT005224, LGALS3, AF156166, SOX4, FAM25A,
AL832615, SLPI, and CRCT1 in a saliva sample of a subject. In one
embodiment, the invention provides a method of detecting or
diagnosing gingivitis in a subject, comprising measuring the level
of NONHSAT006501.2; NONHSAT071649; FAM25A; and CRCT1 in a saliva
sample of a subject.
[0075] In one embodiment, the invention provides a method
monitoring gingivitis regression or response to gingivitis
treatment in a subject, comprising measuring the level of at least
one of NONHSAT006501.2, NONHSAT071649, NONHSAT005224, LGALS3,
AF156166, SOX4, FAM25A, AL832615, SLPI, and CRCT1 in a saliva
sample of a subject.
[0076] Biomarkers
[0077] The present invention provides a biomarker for the detection
of gingivitis. In one embodiment, the biomarkers includes one or
more lncRNAs selected from the group consisting of NONHSAT006501.2,
NONHSAT071649, and NONHSAT005224. In one embodiment, the biomarkers
includes one or more mRNAs selected from the group consisting of
LGALS3, AF156166, SOX4, FAM25A, AL832615, SLPI, and CRCT1.
[0078] In one embodiment, the biomarker comprises NONHSAT006501.2.
In some embodiments NONHSAT006501.2 may also be referred to as
having a GenBank Accession No. of 573288, or as having a gene
symbol of SPRR1A, or as having a Noncode Gene ID of
NONHSAG002962.2, or as having a lncipedia ID of
lnc-SPRR1A-1-1_dup1,lnc-S. In one embodiment NONHSAT006501.2
comprises a nucleotide sequence of:
TABLE-US-00001 (SEQ ID NO: 1)
GTAATGTGGTCCACAGCCATGCCCTTGAGGAGCTGGCCACTGGATACT
GAACACCCTACTCCATTCTGCTTATGAATCCCATTTGCCTATTGACCC
TGCAGTTAGCATGCTGTCACCCTGAATCATAATCGCTCCTTTGCACCT
CTAAAAAGATGTCCCTTACCCTCATTCTGGAGGGCTCCTGAGCCTCTG
CGTAAGGCTGAACGTCTCACTGACTGAGCTAGTCTTCTTGTTGCTCGG
GTGCATTTGAGGATGGATTTGGGGAAGGATCAAGTGAACCATCCCTAG
TCTTCCTTCAATAAATAACTTTTAACTCC.
However, NONHSAT006501.2 is not limited to the sequence of SEQ ID
NO: 1, but rather encompasses other isoforms or variants.
[0079] In one embodiment, the biomarker comprises NONHSAT071649. In
some embodiments NONHSAT071649 may also be referred to as
OTTHUMT00000328143, or as having a. gene symbol of AC073046.25, Of
as having a lncipedia ID of lnc-TET3-2-1_dup1. In one embodiment
NONHSAT071649 comprises a nucleotide sequence of:
TABLE-US-00002 (SEQ ID NO: 2)
CGCTCCGCCCCGGAGGCGGCGGGCAGGCAGCACTGCCTTCTCCAGCGT
CCAGACCCTGGAGGAAAAATACCAGGAGAAACTGCTCACTCAGCTCTG
CCCCCACCACACCCCTACCTGCTCAACTCATGCCTGGGTCCAGGGTGG
GTGAGGGTGAAGAACCCACCGGGCCAAGATGATCCCTTTTCTGAGGGC
TGCTGCTGGTGTCCTCCCCCAGATCCTGGGCCCCAGCAGGTGGGAGAG
TGGCCCCCTACGGAGTCCGATCAGACTGCTGCAGAGGAGGTGAAGAGG
GGTTGAGAAGAGGCATCCATCCACGAGACTGAAGCCACTTGCCTTCAC
CCTTGTAGACTCTTGACTGTTCTAGGCGAGAAGGACCTGTTGGTGGCC TTTGGA.
However, NONHSAT071649 is not limited to the sequence of SEQ ID NO:
2, but rather encompasses other isoforms or variants.
[0080] In one embodiment, the biomarker comprises NONHSAT005224. In
some embodiments NONHSAT005224 may also be referred to as
OTTHUMT00000033693, or as having a gene symbol of RP5-965F6.2, or
as having a lncipedia ID of lnc-ST7L-2-1 dup1. In one embodiment
NONHSAT005224 comprises a nucleotide sequence of:
TABLE-US-00003 (SEQ ID NO: 3)
TTTCTCAGCCTGGAGACTGAAAGCTCTCTTTGGCTGTTGGCCCTCCCA
GGCAGAGTCCACTGGCTGTTAGGGTGAAATGGGGCTGATGCTTCCTGG
AATCCACCAGAAGTATGCAAATTGCACCATCTCTTTCAGCTGCCTGCG
CCTGCATTCCATCGAGGATTCCGGCTCGTCCCCCAGTGGCAACAACTA
GAGAGGAGGTGAGGATCCCCGGCGCTGCCATCTGATAGGCTGTCTCCC
TAGCTCCTCTTGCACTGGCAATCCTTTCATCACACAGGCCTTGTTTTG
AAGGGACCTATTCCACCCACAGTCGTTTCTCACCTCTAGGAGGCCAAA
AAGCTGTAGTCATTGCTGTGGTATCAGGAACTCGAGTTCCTCTCAGAG
GTGTTGTGAAGAGCTTCCCTTCCAACAGTACATGGCCTAAATACCAGG
GAGGAAGTTTCTGACTTTTTCCATCTTCAGTAAAACAGAACCTCTGTT
GTGGATGCAGTGGCTTTGCAAGGAGAGTGGCATTGTCTCTTGGTGAAT
GTAGTTGTTCAAGTCATGG.
However, NONHSAT005224 is not limited to the sequence of SEQ ID NO:
3, but rather encompasses other isoforms or variants.
[0081] In one embodiment, the biomarker comprises LGALS3. In some
embodiments LGALS3 may also be referred to as having a GenBank
Accession No. of NR 003225. In one embodiment LGALS3 comprises a
nucleotide sequence of:
TABLE-US-00004 (SEQ ID NO: 4)
GTGTGCAAATAGAGGAATAAATAGCAGGGCAGCAACTATGTCTGGAGG
TCATTGTCTTTCCTGTCTCAGTAGTAATCAATCACTGCTTATCTTCAA
AAACCCAGAGTAGGGGATGGGGCAGTTAGTGGGGACAGAGGGCAGATG
GGTAAGATTCAGAGCACAGGCTAGTGTGACGGAAGTTTAAACTTGTGA
GTTAAATAGGGTTTGGCAATCTAGCTGGATAGCATCCCTGCCCCTTGA
AGAGATGTTTTTGTGGCGCCACACTACTGACTTAGGCATAATGCCTAG
AGATGGATTAGAACTGCACAATGAACTAGTGGTGAGGTTCAGTTTAAT
GGAAATTGGTGAAAGCTTTTAGGATAAAATGATAATCTTTGTTTCTTT
CAGGAAAATGGCAGACAATTTTTCGGTAAGTGTTTTATGCCTGTTTCT
TCCCCTTGATCAGCTCCACATGGTTGAGGGTTGGGGGTTTTGTTTTTA
CCATGACTTTCCCTTTTCACTCTCCCACTGCGTGGCTTCCCCTGGACT
CATTTGTCCAATGAGGGCTTGCAAGCTGGAGCCTTGTTTTTCCAGCAG
CAGATTTGGGAAGAAAGCCAGGCAGAGCGAGGCCTGGGACTCACTCAC
AGTAACCCTTTCACCAAAAGGCCCAGGGCGGAAGGGAGTGGACTCTGC
CGGCAGGAGCTGAGAAATCCTCTGAGTAGCGGGAAGTGCGGTACAGTC
TGGGCATTCTGATGTTTGTGATTGTTTTTCTCACGGTGATGAAAAAGT
ATGTGCTATAAGTAGAGGAGCGCTAACTCCTGACTTGAGCTAATTATG
AAAATGCAGCCCTCCCTGATCTGAGACGTTGGGAGGCAAGAATAAAGT
GAAAAAGTATATGTAATCCCAACATCTAATTTTAGTCTTAGAAACTCA
AACTATTAATAAGTGGAAAAAGTTTAATGATATGCATGTAATGCCTTT
GCCATATTCCTCTCCTTCTTAGATCACATATTCCTATTTTCCTGAAAA
TTCTGCTTTTGAGAATGCTTTCTGTCCCGTAATTGTGTATGTCTTTCT
TTCCAGCTCCATGATGCGTTATCTGGGTCTGGAAACCCAAACCCTCAA
GGATGGCCTGGCGCATGGGGGAACCAGCCTGCTGGGGCAGGGGGCTAC
CCAGGGGCTTCCTATCCTGGGGCCTACCCCGGGCAGGCACCCCCAGGG
GCTTATCCTGGACAGGCACCTCCAGGCGCCTACCCTGGAGCACCTGGA
GCTTATCCCGGAGCACCTGCACCTGGAGTCTACCCAGGGCCACCCAGC
GGCCCTGGGGCCTACCCATCTTCTGGACAGCCAAGTGCCACCGGAGCC
TACCCTGCCACTGGCCCCTATGGCGCCCCTGCTGGGCCACTGATTGTG
CCTTATAACCTGCCTTTGCCTGGGGGAGTGGTGCCTCGCATGCTGATA
ACAATTCTGGGCACGGTGAAGCCCAATGCAAACAGAATTGCTTTAGAT
TTCCAAAGAGGGAATGATGTTGCCTTCCACTTTAACCCACGCTTCAAT
GAGAACAACAGGAGAGTCATTGTTTGCAATACAAAGCTGGATAATAAC
TGGGGAAGGGAAGAAAGACAGTCGGTTTTCCCATTTGAAAGTGGGAAA
CCATTCAAAATACAAGTACTGGTTGAACCTGACCACTTCAAGGTTGCA
GTGAATGATGCTCACTTGTTGCAGTACAATCATCGGGTTAAAAAACTC
AATGAAATCAGCAAACTGGGAATTTCTGGTGACATAGACCTCACCAGT
GCTTCATATACCATGATATAATCTGAAAGGGGCAGATTAAAAAAAAAA
AAAGAATCTAAACCTTACATGTGTAAAGGTTTCATGTTCACTGTGAGT
GAAAATTTTTACATTCATCAATATCCCTCTTGTAAGTCATCTACTTAA
TAAATATTACAGTGAATTACCTGTCTCAATATGTCAAAAAAAAAAAAA AAAAA.
However, LGALS3 is not limited to the sequence of SEQ ID NO: 4, but
rather encompasses other isoforms or variants.
[0082] In one embodiment, the biomarker comprises AF156166. In some
embodiments AF156166 may also be referred to as having a GenBank
Accession No. of AF156166. In one embodiment AF156166 comprises a
nucleotide sequence of:
TABLE-US-00005 (SEQ ID NO: 5
GAGACTGCATAGGGCTCGGCGTGGATCTTGTTAATGCTGATTCTGGTA
CAGTAGGTCTAGGGCGGGGCCTGAGATTCTGCATTTCTAACAAGAACC
CAGGTGATGCTGACGCTGCTGGGCCAAAAAAGACACTTTGAGTAGCAA
GGGTTAGGCAACCTTTAAAGGGCCCTTCAAGAGTCTAAGATTCCATGA
AGGATACTATTTCCTCTACAAGCTTGTGAAAGTCTTCCAGTGCTACTG
GGAATGGGGTACAGGGATAAATCTCACTGTTTTGACCTCACAGAAGTA
AACCCCTAGAATCATGTTCTCAAAATGAAACACTGGATTGCTGAACTG
ATGGCATTGAGAATTAAGGCTCCAAAATCCTGGGAGTTTCATACCTAA
CTCCACTGCCTTTGCCTTATGATGCACACTGCTCCCTCTATCCCTCCC
TCCCAGGGTCTGCAGAGATGAACTATGCTGTTTTAGGTCTCATTGGTC
CTTATACCTTCCCTAAACCAGGAGGACTTTGGAGCCTGCTGACACAGG
GAGTTCTACATGTCTAAGCACGCAGCTGCTAGAGTCCTCAGCCATCTG
AGCTAAATAGCTGCTCAGAGACAATTAGTACACCTCCGTATYTTACAG
ATAAAGGAACTGAAGTCCAAACAAGCCAAGCTACCCAACCAAGGCTCA
CAGCAGGCAAGAGGATAAAAACCATGTCCTTTGACTCCCAGGTTAGTT TT.
However, AF156166 is not limited to the sequence of SEQ ID NO: 5,
but rather encompasses other isoforms or variants.
[0083] In one embodiment, the biomarker comprises SOX4. In some
embodiments SOX4 may also be referred to as having a GenBank
Accession No. of AJ420500. In one embodiment SOX4 comprises a
nucleotide sequence of:
TABLE-US-00006 (SEQ ID NO: 6)
CCACGCGTCCGCATATTTTTTCTTTTGTCCCTTTTTTTCTTTCCTTTC
TTTTTACTTCCTTTATTTCTTTATTCCTTCCTTTTCCTTTTTTTCTTT
TTTTTTTCTTTTTTTTTTTTTTTTGGTAGTTGTTGTTACCCACGCCAT
TTTACGTCTCCTTCACTGAAGGGCTAGAGTTTTAACTTTTAATTTTTT
ATATTTAAATGTAGACTTTTGACACTTTTAAAAAACAAAAAAAGACAA
GAGAGATGAAAACGTTTGATTATTTTCTCAGTGTATTTTTGTAAAAAA
TATATAAAGGGGGTGTTAATCGGTGTAAATCGCTGTTTGGATTTCCTG
ATTTTATAACAGGGCGGCTGGTTAATATCTCACACAGTTTAAAAAATC
AGCCCCTAATTTCTCCATGTTTACACTTCAATCTGCAGGCTTCTTAAA
GTGACAGTATCCCTTAACCTGCCACCAGTGTCCACCCTCCGGCCCCCG
TCTTGTAAAAAGGGGAGGAGAATTAGCCAAACACTGTAAGCTTTTAAG
AAAAACAAAGTTTTAAACGAAATACTGCTCTGTCCAGAGGCTTTAAAA
CTGGTGCAATTACAGCAAAAAGGGATTCTGTAGCTTTAACTTGTAAAC
CACATCTTTTTTGCACTTTTTTTATAAGCAAAAACGTGCCGTTTAAAC
CACTGGATCTATCTAAATGCCGATTTGAGTTCGCGACACTATGTACTG
CGTTTTTCATTCTTGTATTTGACTATTTAATCCTTTCTACTTGTCGCT
AAATATAATTGTTTTAGTCTTATGGCATGATGATAGCATATGTGTTCA
GGTTTATAGCTGTTGTGTTTAAAAATTGAAAAAAGTGGAAAACATCTT
TGTACATTTAAGTCTGTATTATAATAAGCAAAAAGATTGTGTGTATGT
ATGTTTAATATAACATGACAGGCACTAGGACGTCTGCCTTTTTAAGGC
AGTTCCGTTAAGGGTTTTTGTTTTTAAACTTTTTTTTGCCATCCATCC
TGTGCAATATGCCGTGTAGAATATTTGTCTTAAAATTCAAGGCCACAA
AAACAATGTTTGGGGGAAAAAAAAGAAAAAATCATGCCAGCTAATCAT
GTCAAGTTCACTGCCTGTCAGATTGTTGATATATACCTTCTGTAAATA
ACTTTTTTTGAGAAGGAAATAAAATCAGCTGGAACTGAACCCTAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGG.
However, SOX4 is not limited to the sequence of SEQ ID NO: 6, but
rather encompasses other isoforms or variants.
[0084] In one embodiment, the biomarker comprises FAM25A. In some
embodiments FAM25A may also be referred to as having a GenBank
Accession No. of NM_001146157, XM_001723781, XM_002343005,
XM_926530, or XM_937048. In one embodiment FAM25A comprises a
nucleotide sequence of:
TABLE-US-00007 (SEQ ID NO: 7)
TCAGCATCCTAGTTCACCACTGTCTGCTGCCACACGATGCTGGGAGGC
CTGGGGAAGCTGGCTGCCGAAGGCCTGGCCCACCGCACCGAGAAGGCC
ACCGAGGGAGCCATTCATGCCGTGGAAGAAGTGGTGAAGGAGGTGGTG
GGACACGCCAAGGAGACTGGAGAGAAAGCCATTGCTGAAGCCATAAAG
AAAGCCCAAGAGTCAGGGGACAAAAAGATGAAGGAAATCACTGAGACA
GTGACCAACACAGTCACAAATGCCATCACCCATGCAGCAGAGAGTCTG
GACAAACTTGGACAGTGAGTGCACCTGCTACCACGGCCCTTCCCCAGT
CTCAATAAAAAGCCATGACATGTGTA.
However, FAM25A is not limited to the sequence of SEQ ID NO: 7, but
rather encompasses other isoforms or variants.
[0085] In one embodiment, the biomarker comprises AL832615. In some
embodiments AL832615 may also be referred to as having a GenBank
Accession No. of AL832615. In one embodiment AL832615 comprises a
nucleotide sequence of:
TABLE-US-00008 (SEQ ID NO: 8)
GTGGCTCTTGAGCATGGGTGGGGGAAGCCCCCACATATCTGAGTCAGT
GCCACCTGGACACTACCCTTGGAGCATCCTGCTGAGGTGGCCATTCAG
GTTTTCTTTCCTTTCCTTTTATTCCACTGTTTGCCTCGGACATGAAAC
ATCTCACAGACTGCCTGGAAGAAGGTGGAGCAGACTGGGGTTAATGGT
CAGCAGCAGCAGCATCCCCACCACTGGGGCTATCCCTTTTTAGGCCCT
TACCATGGGCCAAACACTGAGCCGTGTGCTTCGTGTAACTTCTAAGCA
CGCTTACCTGATAGAGTGCCAGCAAAGACTCAAAGAGGTGCCTGGGCT
TGGCACATAGTAGCTATTGCTACTATTATGAATGTTGTTTTGTCTTTG
TTTTTGTTTTGAGACAGGGCCTCACTCTGTTGCCCAGGTTGGAGTACA
GCAGTGCCATCATGGCTCACTGAGGCCTCAACCTCCCTGGGTTTGGGC
AGTCCTCCCGCCTCGGCCTCCCGAGTGGCTGGGACTACAGGTGTGCGC
CACCAAGCCCGGCCGGTTTTTTGTATTTTCAGTAGAGACTGGTTTTGC
CAAGTCGCCCAGGCTGGTTTCGAACTCTGTGATCCCAGCACTTTGGGA
GGCCGAGGCGGGTGGATCATGAGGTCAGGAGATCGAGACCATCCTGGC
TAACAAGGTGAAGCCCCGTCTCTACTGAAAATACAAAAAATTGGCCGG
GCGCGGTGGCGGGCGCCTGTGGTCCCAGCTGCTCGGGAGGCTGAGGCG
GGAGAATGGCGTGAACCCGGGAAGCGGAGCTTGCAGTGAGCCGAGATT
GCGCCACTGCGGTCCGCAGTCCAGCCTGGGCGACAGAGCGAGACTCTG
TCTCAAAAAAAAAAAAAAAAAAAAAAAATGCCAAGCTCACCCAGAAAT
AACCCCGTGCATATATGGTCAACAGATCTTTGACAAGGCCATCAAGGA
TATACAATGTAGATTCTTTTATTCCTTTACTTTCTTAATAGACTTGCT
TTCACTGTACTGTAAAAAAAAAAAAGGCACAATGTAGAAAGGAAACTC
TCTTCAATGAATGGTGTTGGGGAAAGTGCATGAAAAAGAATGAAATTG
CACACTTGTTTTACATCATATACAGAAAATTAGCTCAAAGTGGATTAA
AGATTTAAATGTAATATCTGAAACCATGTAAATCCTGGAAGTAAACAT
AGGGAAAAATCTCCTCGACATTGGTCATAATTGGCAATATTTTTTTTG
ATGTAACACCAAAGCACAGGCAACAAAAGTGAAAATAAATAAATGGGA
CTACATCAATCTTAAAAGGTTTTACACAGCAAAGGAAACCATGACAAA
ATGAAAAGGCAACCTACGGGATGGAAGAAAATATTTGCGACCCATATA
TTTGATAAGGGGTTATTTGAAAAAATATAAGGAATTCACACAATTCAA
TAGCAAAAATTAATAAATACATGAATAACGCAATTAAAAATAGGCAAA
GGACCCCAATGGACTTTTTTCCCCAAGGAAGATATACAAATGGCCAGC
CAGCATATGAAAAGGTGCTCAACACCACTAATCATCAGAGAAATGCAA
ATCAAAACCACAGTGAGATATTGCCTCATAGGGTAGGATGGCTCTTAT
AAAAAAACGACAAGAGATAACAAGTGTTGGCGAAAGCATAGAGGAAAG
AGAACCCTTGTACACTGTTGGTTGGAATGTAAAGTGGTATAACCTTTA
CAGAAAACAGTATGGAGGTTCCTCAAAAAATTAGAAGCAGAACTACCA
TACGATTCAGCAATCAGGTTAGAACCTTGAAGAGAGATCTGCGCCCCA
TGTTTATTACAACACTATTCACAATACCCAAGATATGGAAACAGCCTA
AGTGTCCAGCAACAGATGAATGGATAAATAAAATACATATAAACAATG
GACTATTAGCCATTCAAAAGAAGAAACTCCTGTCCTGGATAAACCTGG
AGGACATTACGCTAAGTGAAATAAGCCAGACACCGAAAGACAAGTTTT
GTATGATCTCACTTATATGTGGGATCTAAGAGAGTCAAACTCATAAAA
ACAGATAGTAGAATGGTGGTTGCCAAGGGCTGGAGGTGGGGAAAATGG
GAAGCTATTAATCAAAGGGTGTAAACTTTCAGTTATAAGATGAACAAA
TTCTGGAGATTTAATGTACAGCATAGGTGGTAATGGATGTAATAAATT
TGATTGTGATAATTAGTACACAATATATACATATATGAAATCATCACA
TTGTATGCATTAAATATACACAATCCTTGTCAACTCAATATTTTTAAA
AAAATGTTTAAAATGCCTAGGTCATAAGAATTCTGAGAATGAAATACA
ACAACATACATGAATGGACCTGCTACACAGAAGGTGCTAAATAGGTTT
GTTTTGTTTTATTTTATTTCAACTCTGGCAGATGTAGACCTATTGGGA
AAGAATATAGAATGCACTTGTGCACAAGGATTATCTATACGATGGTTA
AATATCCTGCATACATGCCATGTCATTTCTACTCCTCAGTCAATGGAT
AATAAAAGCAGAACCAGCCTTCTGGTGGTCACAAAACATTTTGACATG
AGAAAGGCTGATCATGAGCAATCTGGCAATGTACATCCCAGAGCGTGC
ATGCCCTTTGACCCACAGCTACCATGATGTCATGTCTAGCAATTAGTC
CTAAGGAGATGATCAGAGATGTGTAAAGAGATTTCATTCTAACAGCAT
CCTCTGTAGTGGTATATGTCAGGGGCTGGTAAGCCATGTCCAGAGGAG
CAGGCTGCATCTGGTCCACCACCTGTTTTTGTAAAGTTTATCAGAACA
CAGTCATGCCCATTCATTTACAAATTGTGTATGGCTTCTTTCCCTGCA
ACAGCAGAGTTGAGTGTTGCAACAGAAACCTATGGCCTGCAGAGTTTA
AAATATCTACCCTTTGGCCTTTTATAAAAAAAGTTTACTGATTCCTGG
TGAGTATATTAAAAAGTTAGGAAAACCTAAATCTTCCAGAGTGGAGAA
TTAGAAAGTAAGACGTGTTGTATATAAGACAGACAGTTTGTGTGTGCG
TTTATTTATAAATATATTATTTTGAAATAATGTTGTCGACATATGTTG
CAGGTCTTAAAAATTGGTCAATATATAGTGTTAATCAAAAAATGGCAA
ATTGTAAAATGTAGACAGAATGTGATTGTGTATTTTGTGCATACACCA
ACAGAAAAGGGTGCTAGGAAACCTGTGGACCAACATACTAAGTGTGGC
TCTTTTGATGGTGGTATCATGGATTTTTAAAAATCTTCTTGGTTTTCT
GTAGATTCTGACTTTCCTGTAATGAGTATGAATAAGTATGTATTTCTT
GAGAAATGAGAAAATAACTTTATCTTCCCAGATTTCTCATAATTGAAA
ATGTTGGAATAAATGGTCCTGGGACAGATCTTTCCATTGAGAAGGGCG
GAAGGGAAACCCTGGGGATTCAGCTGGGTTTCTGTTGCATTTCTGGTA
ACACACAGTTGTGAAAAGCCAGTGTTGGCCATTCCCCAGGACAGTCTG
GGGTAGAGGAGGTCAGGATTTAACTACTTGAGGGTCCGGGGAACAGAT
GTGGCCACAGTCCTTCCTGACTCACTGTTTTCCCTTCCACAGTCCCCG
TCTTCTCTTCACTGATGCACATAGATGCCTGACCAGAGGAGAGATTTA
GTTTTCGTCCAAGGATTATCTGTTATGTTGCAGTTCTGAAATTCCCAT
AACGTTTAGGCTAGAACACAAGTGATTTCATTATCTCCAATGTGTATG
GCTTGATAGAAATAGATTCCATTATGTAGCACCTTAAATCCAGATAAA
ACATAAGGAATTTCTATTCCATGTTTGTATGATCAATGTTAATAATCT
AAGAAAATCTAAAAAGAAGCTACTTCCTCTATTACAGTATGAAATAAA
TATGCTGAATGATTTGTCTTGGGGGGTGGAATGGAAAGGTATAAGACT
GAGGAGGGTGCCTGTGGGAACAGTGATAGGAATCCTTTCTTAAGGGTT
GGGTTTTACATACGTCTTTTAAAATAGATGATATCATTAATAAATTAT
CTGTGGGCATCATGAAAAAAGTGTATAACGTACAACTTTATGAGCTTG
ACAGTTGGTGAAAACTTTTCTGTTTAAAATTTTATTTGGCCCTCCCCA
AAAGAAATGTTTATTTATGAGTATTAGGATAGTTCCAGCAGTAATGCC
TCAAAAGAACCAGGAGGTATAGTGTTGTCTAAAATGTGGACTCAGGAG
CCAGACTGCCTGGCTGTGCAACTAGCCTTGTCACTTCCTAGATATGTG
GCAAGTTAATTAACTTCTCAGTGTTCTTATCTGTAGAATGGGGATAAT
CCTAATATACATCTCAGGGTTATATTACAAATTTGAGAAGTTAATTTT
GTAAAGGACTTAGAATGATATCTGGCAAATAAAAGTGTTCATAAAAGC AAAAAAA.
However, AL832615 is not limited to the sequence of SEQ ID NO: 8,
but rather encompasses other isoforms or variants.
[0086] In one embodiment, the biomarker comprises SLPI. In some
embodiments SLPI may also be referred to as having a GenBank
Accession No. of NM_003064. In one embodiment SLPI comprises a
nucleotide sequence of:
TABLE-US-00009 (SEQ ID NO: 9)
CAGAGTCACTCCTGCCTTCACCATGAAGTCCAGCGGCCTCTTCCCCTT
CCTGGTGCTGCTTGCCCTGGGAACTCTGGCACCTTGGGCTGTGGAAGG
CTCTGGAAAGTCCTTCAAAGCTGGAGTCTGTCCTCCTAAGAAATCTGC
CCAGTGCCTTAGATACAAGAAACCTGAGTGCCAGAGTGACTGGCAGTG
TCCAGGGAAGAAGAGATGTTGTCCTGACACTTGTGGCATCAAATGCCT
GGATCCTGTTGACACCCCAAACCCAACAAGGAGGAAGCCTGGGAAGTG
CCCAGTGACTTATGGCCAATGTTTGATGCTTAACCCCCCCAATTTCTG
TGAGATGGATGGCCAGTGCAAGCGTGACTTGAAGTGTTGCATGGGCAT
GTGTGGGAAATCCTGCGTTTCCCCTGTGAAAGCTTGATTCCTGCCATA
TGGAGGAGGCTCTGGAGTCCTGCTCTGTGTGGTCCAGGTCCTTTCCAC
CCTGAGACTTGGCTCCACCACTGATATCCTCCTTTGGGGAAAGGCTTG
GCACACAGCAGGCTTTCAAGAAGTGCCAGTTGATCAATGAATAAATAA
ACGAGCCTATTTCTCTTTGCAC.
However, SLPI is not limited to the sequence of SEQ ID NO: 9, but
rather encompasses other isoforms or variants.
[0087] In one embodiment, the biomarker comprises CRCT1. In some
embodiments CRCT1 may also be referred to as having a GenBank
Accession No. of NM_019060, in one embodiment CRCT1 comprises a
nucleotide sequence of:
TABLE-US-00010 (SEQ ID NO: 10)
GCCCATTCCAGTTGGAGAACGTAGTGAGTCTTTCAGTGGAGCCAGGGT
CTGGTTTGTCGTGAGGAGCTCCGCGATGTCCTCTCAACAGAGCGCCGT
TTCCGCCAAAGGCTTTTCCAAGGGGTCGTCCCAGGGCCCCGCTCCGTG
TCCCGCCCCGGCGCCCACCCCGGCGCCCGCCTCCTCCTCCTCCTGCTG
CGGCTCCGGCAGGGGCTGCTGCGGCGACTCAGGCTGCTGCGGCTCCAG
CTCCACCAGTTGCTGCTGCTTCCCAAGGAGACGCCGCCGACAGCGGAG
TAGTGGTTGCTGCTGCTGCGGGGGCGGCAGCCAGAGGTCCCAGCGCTC
CAACAACCGGAGCTCAGGATGCTGCTCCGGCTGCTGAGAGGCCCGCAA
CCCCCAGCGCTGCGCTAGAGAAACCCGCCCAGCCCAGAGCGGGCCCGC
CCCGCTGCGGCTCCCACGCGGGGCTGGGCCTCGGAGTTTGCCCCGTAA
AGCGAATTGCACTTTGATGTTCAGAAACCCACTTTGTTCTCAGCCACG
CAAAACTCCCTGACCCCGATGTGATTTTTCTCCCCGGGGATTCGAGAG
CCATGCGTGGGACACTGGACCCTACTGTCTACACGGGCTTGCACACAG
CAGGTGCTCAGCAAATGTCTATTGATTTGATTGTCTTTTGAAGATGTC
ATAATAAAGCTTCTACCTCCTGAAAAA.
However, CRCT1 is not limited to the sequence of SEQ ID NO: 10, but
rather encompasses other isoforms or variants.
Identifying a Marker or Biomarker
[0088] The invention includes methods for the identification of
markers differentially expressed between samples of healthy
subjects and subjects with gingivitis. In some embodiments, the
invention includes methods for identification of markers
differentially expressed between samples obtained over time from a
subject being monitored or treated with a gingivitis treatment.
[0089] The invention contemplates the identification of
differentially expressed markers by whole genome nucleic acid
microarray, PCR, or immunoassay. The invention further contemplates
using methods known to those skilled in the art to detect and to
measure the level of differentially expressed marker expression
products, such as RNA and protein, to measure the level of one or
more differentially expressed marker expression products.
[0090] Methods of detecting or measuring gene expression may
utilize methods that focus on cellular components (cellular
examination), or methods that focus on examining extracellular
components (fluid examination). Because gene expression involves
the ordered production of a number of different molecules, a
cellular or fluid examination may be used to detect or measure a
variety of molecules including RNA, protein, and a number of
molecules that may be modified as a result of the protein's
function. Typical diagnostic methods focusing on nucleic acids
include amplification techniques such as PCR and RT-PCR (including
quantitative variants), and hybridization techniques such as in
situ hybridization, microarrays, blots, and others. Typical
diagnostic methods focusing on proteins include binding techniques
such as ELISA, immunohistochemistry, microarray and functional
techniques such as enzymatic assays.
[0091] The genes identified as being differentially expressed may
be assessed in a variety of nucleic acid detection assays to detect
or quantify the expression level of a gene or multiple genes in a
given sample. For example, traditional Northern blotting, nuclease
protection, RT-PCR, microarray, and differential display methods
may be used for detecting gene expression levels. Methods for
assaying for mRNA include Northern blots, slot blots, dot blots,
and hybridization to an ordered array of oligonucleotides. Any
method for specifically and quantitatively measuring a specific
protein or mRNA or DNA product can be used. However, methods and
assays are most efficiently designed with array or chip
hybridization-based methods for detecting the expression of a large
number of genes. Any hybridization assay format may be used,
including solution-based and solid support-based assay formats.
[0092] The protein products of the genes identified herein can also
be assayed to determine the amount of expression. Methods for
assaying for a protein include Western blot, immunoprecipitation,
and radioimmunoas say. The proteins analyzed may be localized
intracellularly (most commonly an application of
immunohistochemistry) or extracellularly (most commonly an
application of immunoassays such as ELISA).
[0093] Biological samples may be of any biological tissue or fluid
containing saliva. Frequently the sample will be a "clinical
sample" which is a sample derived from a patient. The biological
sample may contain any biological material suitable for detecting
the desired biomarkers, and may comprise cellular and/or
non-cellular material obtained from the individual. One example of
a biological sample is a whole saliva sample. Another example of a
biological sample is a cell-free saliva sample. Another example of
a biological sample is a saliva supernatant, such as the
supernatant obtained after centrifuging a saliva sample. Another
example of a biological sample is the material in a pellet obtained
from a saliva sample, such as a pellet obtained after centrifuging
a saliva sample (i.e., saliva pellet). In another example, the
biological sample is the pellet obtained from centrifuging another
biological sample, including, but not limited to, blood, gingival
crevicular fluid, and the like.
[0094] Controls group samples may either be from normal subject or
samples from subjects with a known severity of gingivitis. In some
embodiments a control sample is a baseline sample obtained from a
subject before a treatment regimen is initiated. In some
embodiments, a control sample is a sample obtained from a subject
at an earlier time point.
[0095] As described below, comparison of the expression patterns of
the sample to be tested with those of the controls can be used to
diagnose gingivitis, monitor gingivitis, or evaluate the response
to gingivitis treatment. In some instances, the control groups are
only for the purposes of establishing initial cutoffs or thresholds
for the assays of the invention. Therefore, in some instances, the
systems and methods of the invention can diagnose gingivitis
without the need to compare with a control group.
Methods of Diagnosis
[0096] The present invention relates to the identification of
biomarkers associated with gingivitis. Accordingly, the present
invention features methods for identifying subjects having
gingivitis, or who are at risk of developing gingivitis, including
those subjects who are asymptomatic or only exhibit non-specific
indicators of gingivitis by detection of the biomarkers disclosed
herein.
[0097] These biomarkers are also useful for monitoring subjects
undergoing treatments and therapies for gingivitis, and for
selecting or modifying therapies and treatments that would be
efficacious in subjects having gingivitis, wherein selection and
use of such treatments and therapies slow the progression of
gingivitis, or prevent its onset.
[0098] The invention provides improved methods for the diagnosis
and prognosis of gingivitis. The risk of developing gingivitis can
be assessed by measuring one or more of the biomarkers described
herein, and comparing the measured values to comparator values,
reference values, or index values. Such a comparison can be
undertaken with mathematical algorithms or formula in order to
combine information from results of multiple individual biomarkers
and other parameters into a single measurement or index. Subjects
identified as having an increased risk of gingivitis can optionally
be selected to receive treatment regimens, such as prophylactic or
therapeutic agents, dental procedures, periodontal procedures, or
oral hygiene counseling to prevent, treat or delay the onset of
gingivitis.
[0099] Identifying a subject before they develop gingivitis enables
the selection and initiation of various therapeutic interventions
or treatment regimens in order to delay, reduce or prevent that
subject's conversion to a disease state. Monitoring the levels of
at least one biomarker also allows for the course of treatment of
gingivitis to be monitored. For example, a sample can be provided
from a subject undergoing treatment regimens or therapeutic
interventions for gingivitis. Such treatment regimens or
therapeutic interventions can include administration of
pharmaceuticals, therapeutics or prophylactics; professional dental
cleaning; scaling and root planning; use of chlorohexidine rinses;
use of toothpastes containing Stannous, Zinc, Triclosan, and/or
hydrogen peroxide; use of mouthwashes containing Triclosan,
Cetylpyridinium chloride, other quats (e.g., BKC) and/or essential
oils; and at-home oral hygiene regimens. Samples can be obtained
from the subject at various time points before, during, or after
treatment.
[0100] The biomarkers of the present invention can thus be used to
generate a biomarker profile or signature of the subjects: (i) who
do not have and are not expected to develop gingivitis and/or (ii)
who have or expected to develop gingivitis. The biomarker profile
of a subject can be compared to a predetermined or comparator
biomarker profile or reference biomarker profile to diagnose or
identify subjects at risk of developing gingivitis, to monitor the
progression of disease, as well as the rate of progression of
disease, and to monitor the effectiveness of treatments. Data
concerning the biomarkers of the present invention can also be
combined or correlated with other data or test results, such as,
without limitation, measurements of clinical parameters or other
algorithms for gingivitis. Other data includes gender, age,
ethnicity, height, weight, diet, genetics, smoking,
mouth-breathing, mouth-breathing during sleep, obesity, heart
disease, osteoporosis, hypertension, diabetes, bowel diseases,
muscle and joint disease, tumor, mental illness, caries, missing
teeth, level of oral hygiene, level of dental care utilization, and
use of medications that dry the mouth, and the like. In some
embodiments, the data includes results of one or more assays for
gingivitis, including, but not limited to Loe-Silness Gingival
Index (GI), Quigley and Hein Plaque Index (PI),
Turesky-modification of the Quigly and Hein index, gingival
bleeding index, Navy index, modified Navy index, bleeding on
probing (BOP), and probing depth (PD). The data can also comprise
subject information such as medical history and any relevant family
history.
[0101] The present invention also provides methods for identifying
agents for treating or preventing gingivitis that are appropriate
or otherwise customized for a specific subject. In this regard, a
test sample from a subject, exposed to a therapeutic agent or a
drug, can be taken and the level of one or more biomarkers can be
determined. The level of one or more biomarkers can be compared to
a sample derived from the subject before and after treatment, or
can be compared to samples derived from one or more subjects who
have shown improvements in risk factors as a result of such
treatment or exposure.
[0102] In various embodiments, methods are disclosed herein that
may be of use to determine whether a subject has gingivitis. In
some embodiments, these methods may utilize a biological sample
(such as urine, saliva, blood, serum, amniotic fluid, gingival
crevicular fluid, or tears), for the detection of one or more
markers of the invention in the sample.
[0103] In one embodiment, the biomarker for the detection of
gingivitis, includes but is not limited to at least one of
NONHSAT006501.2, NONHSAT071649, NONHSAT005224, LGALS3, AF156166,
SOX4, FAM25A, AL832615, SLPI, and CRCT1.
[0104] In one embodiment, the method comprises detecting that at
least one biomarker selected from NONHSAT071649, NONHSAT005224,
AF156166, and SOX4 is upregulated as compared to a comparator
control. For example, in one embodiment, the method comprises
detecting that the level of at least one biomarker selected from
NONHSAT071649, NONHSAT005224, AF156166, and SOX4 is increased as
compared to the level of the at least one biomarker in a comparator
control.
[0105] In one embodiment, the method comprises detecting that at
least one biomarker selected from NONHSAT006501.2, LGALS3, FAM25A,
and CRCT1 is downregulated as compared to a comparator control. For
example, in one embodiment, the method comprises detecting that the
level of at least one biomarker selected from NONHSAT006501.2,
LGALS3, FAM25A, and CRCT1 is decreased as compared to the level of
the at least one biomarker in a comparator control.
[0106] In one embodiment, the method comprises detecting one or
more markers in a biological sample of the subject. In one
embodiment, the biological sample is saliva. In various
embodiments, the level of one or more of markers of the invention
in the biological sample of the subject is compared with the level
of the biomarker in a comparator. Non-limiting examples of
comparators include, but are not limited to, a negative control, a
positive control, standard control, standard value, an expected
normal background value of the subject, a historical normal
background value of the subject, a reference standard, a reference
level, an expected normal background value of a population that the
subject is a member of, or a historical normal background value of
a population that the subject is a member of.
[0107] In another embodiment, the invention is a method of
monitoring the progression or regression of gingivitis in a subject
by assessing the level of one or more of the markers of the
invention in a biological sample of the subject. In one embodiment,
the invention provides a method of monitoring the response of a
gingivitis treatment in a subject by assessing the level of one or
more of the markers of the invention in a biological sample of the
subject.
[0108] In one embodiment, the invention provides determining that
gingivitis is regressing in a subject by detecting that at least
one biomarker selected from NONHSAT071649, NONHSAT005224, AF156166,
and SOX4 is downregulated as compared to a comparator control. For
example, in one embodiment, the method comprises detecting that the
level of at least one biomarker selected from NONHSAT071649,
NONHSAT005224, AF156166, and SOX4 is decreased as compared to the
level of the at least one biomarker in a comparator control.
[0109] In one embodiment, the invention provides determining that
gingivitis is regressing in a subject by detecting that at least
one biomarker selected from NONHSAT006501.2, LGALS3, FAM25A, and
CRCT1 is upregulated as compared to a comparator control. For
example, in one embodiment, the method comprises detecting that the
level of at least one biomarker selected from NONHSAT006501.2,
LGALS3, FAM25A, and CRCT1 is increased as compared to the level of
the at least one biomarker in a comparator control.
[0110] In one embodiment, the invention provides determining that a
subject is responsive to a gingivitis treatment by detecting that
at least one biomarker selected from NONHSAT071649, NONHSAT005224,
AF156166, and SOX4 is downregulated as compared to a comparator
control. For example, in one embodiment, the method comprises
detecting that the level of at least one biomarker selected from
NONHSAT071649, NONHSAT005224, AF156166, and SOX4 is decreased as
compared to the level of the at least one biomarker in a comparator
control.
[0111] In one embodiment, the invention provides determining that a
subject is responsive to a gingivitis treatment by detecting that
at least one biomarker selected from NONHSAT006501.2, LGALS3,
FAM25A, CRCT1 is upregulated as compared to a comparator control.
For example, in one embodiment, the method comprises detecting that
the level of at least one biomarker selected from NONHSAT006501.2,
LGALS3, FAM25A, CRCT1 is increased as compared to the level of the
at least one biomarker in a comparator control.
[0112] In some embodiments, the comparator control is a baseline
level of the one or more biomarkers, for example the baseline level
of the one or more biomarkers obtained prior to the initiation of
the treatment. In some embodiments, the comparator control is the
level of one or more biomarkers in a sample obtained at an earlier
time point in the treatment regimen.
[0113] In various embodiments, the subject is a human subject, and
may be of any race, sex and age.
[0114] Information obtained from the methods of the invention
described herein can be used alone, or in combination with other
information (e.g., disease status, disease history, vital signs,
blood chemistry, etc.) from the subject or from the biological
sample obtained from the subject.
[0115] In various embodiments of the methods of the invention, the
level of one or more markers of the invention is determined to be
increased when the level of one or more of the markers of the
invention is increased by at least 10%, by at least 20%, by at
least 30%, by at least 40%, by at least 50%, by at least 60%, by at
least 70%, by at least 80%, by at least 90%, or by at least 100%,
when compared to with a comparator.
[0116] In other various embodiments of the methods of the
invention, the level of one or more markers of the invention is
determined to be decreased when the level of one or more of the
markers of the invention is decreased by at least 10%, by at least
20%, by at least 30%, by at least 40%, by at least 50%, by at least
60%, by at least 70%, by at least 80%, by at least 90%, or by at
least 100%, when compared to with a comparator.
[0117] In the methods of the invention, a biological sample from a
subject is assessed for the level of one or more of the markers of
the invention in the biological sample obtained from the patient.
The level of one or more of the markers of the invention in the
biological sample can be determined by assessing the amount of
polypeptide of one or more of the biomarkers of the invention in
the biological sample, the amount of RNA of one or more of the
biomarkers of the invention in the biological sample, the amount of
enzymatic activity of one or more of the biomarkers of the
invention in the biological sample, or a combination thereof.
Detecting a Biomarker
[0118] In one embodiment, the invention includes detecting an RNA
in a bodily fluid, wherein the bodily fluid is saliva and the RNA
is detected in saliva. In another embodiment, the invention
includes detecting an extracellular RNA in a bodily fluid, wherein
the bodily fluid is saliva and the extracellular RNA is detected in
a cell-free fluid phase portion of saliva. In some embodiments,
detection of mRNAs is performed in a portion of saliva (e.g.,
supernatant, cell-free fluid phase) wherein presence of
microorganisms and the extraneous substances such as food debris is
minimized, which allows analyzing the molecules in simple and
accurate fashion. In some embodiments, the cell-free fluid phase
portion of derived from unstimulated saliva.
[0119] In one embodiment, detecting extracellular RNAs herein also
informative RNAs, is performed in a bodily fluid, saliva, that
meets the demands of an inexpensive, non-invasive and accessible
bodily fluid to act as an ideal medium for investigative
analysis.
[0120] Biomarkers generally can be measured and detected through a
variety of assays, methods and detection systems known to one of
skill in the art. Various methods include but are not limited to
refractive index spectroscopy (RI), ultra-violet spectroscopy (UV),
fluorescence analysis, electrochemical analysis, radiochemical
analysis, near-infrared spectroscopy (near-IR), infrared (IR)
spectroscopy, nuclear magnetic resonance spectroscopy (NMR), light
scattering analysis (LS), mass spectrometry, pyrolysis mass
spectrometry, nephelometry, dispersive Raman spectroscopy, gas
chromatography, liquid chromatography, gas chromatography combined
with mass spectrometry, liquid chromatography combined with mass
spectrometry, matrix-assisted laser desorption ionization-time of
flight (MALDI-TOF) combined with mass spectrometry, ion spray
spectroscopy combined with mass spectrometry, capillary
electrophoresis, colorimetry and surface plasmon resonance (such as
according to systems provided by Biacore Life Sciences). See also
PCT Publications WO/2004/056456 and WO/2004/088309. In this regard,
biomarkers can be measured using the above-mentioned detection
methods, or other methods known to the skilled artisan. Other
biomarkers can be similarly detected using reagents that are
specifically designed or tailored to detect them.
[0121] Different types of biomarkers and their measurements can be
combined in the compositions and methods of the present invention.
In various embodiments, the protein form of the biomarkers is
measured. In various embodiments, the nucleic acid form of the
biomarkers is measured. In exemplary embodiments, the nucleic acid
form is RNA. In various embodiments, measurements of protein
biomarkers are used in conjunction with measurements of nucleic
acid biomarkers.
[0122] Methods for detecting mRNA, such as RT-PCR, real time PCR,
branch DNA, NASBA and others, are well known in the art. Using
sequence information provided by the database entries for the
biomarker sequences, expression of the biomarker sequences can be
detected (if present) and measured using techniques well known to
one of ordinary skill in the art. For example, sequences in
sequence database entries or sequences disclosed herein can be used
to construct probes for detecting biomarker RNA sequences in, e.g.,
Northern blot hybridization analyses or methods which specifically,
and in some instances, quantitatively, amplify specific nucleic
acid sequences. As another example, the sequences can be used to
construct primers for specifically amplifying the biomarker
sequences in, e.g., amplification-based detection methods such as
reverse-transcription based polymerase chain reaction (RT-PCR).
When alterations in gene expression are associated with gene
amplification, deletion, polymorphisms and mutations, sequence
comparisons in test and reference populations can be made by
comparing relative amounts of the examined DNA sequences in the
test and reference cell populations. In addition to Northern blot
and RT-PCR, RNA can also be measured using, for example, other
target amplification methods (e.g., TMA, SDA, NASBA), signal
amplification methods (e.g., bDNA), nuclease protection assays, in
situ hybridization and the like.
[0123] The concentration of the biomarker in a sample may be
determined by any suitable assay. A suitable assay may include one
or more of the following methods, an enzyme assay, an immunoassay,
mass spectrometry, chromatography, electrophoresis or an antibody
microarray, or any combination thereof. Thus, as would be
understood by one skilled in the art, the system and methods of the
invention may include any method known in the art to detect a
biomarker in a sample.
[0124] The invention described herein also relates to methods for a
multiplex analysis platform. In one embodiment, the method
comprises an analytical method for multiplexing analytical
measurements of markers. In another embodiment, the method
comprises a set of compatible analytical strategies for multiplex
measurements of markers and/or metabolites in saliva.
Kits
[0125] The present invention also pertains to kits useful in the
methods of the invention. Such kits comprise various combinations
of components useful in any of the methods described elsewhere
herein, including for example, materials for quantitatively
analyzing a biomarker of the invention (e.g., polypeptide and/or
nucleic acid), materials for assessing the activity of a biomarker
of the invention (e.g., polypeptide and/or nucleic acid), and
instructional material. For example, in one embodiment, the kit
comprises components useful for the quantification of a desired
nucleic acid in a biological sample. In another embodiment, the kit
comprises components useful for the quantification of a desired
polypeptide in a biological sample. In a further embodiment, the
kit comprises components useful for the assessment of the activity
(e.g., enzymatic activity, substrate binding activity, etc.) of a
desired polypeptide in a biological sample.
[0126] In a further embodiment, the kit comprises the components of
an assay for monitoring the effectiveness of a treatment
administered to a subject in need thereof, containing instructional
material and the components for determining whether the level of a
biomarker of the invention in a biological sample obtained from the
subject is modulated during or after administration of the
treatment. In various embodiments, to determine whether the level
of a biomarker of the invention is modulated in a biological sample
obtained from the subject, the level of the biomarker is compared
with the level of at least one comparator control contained in the
kit, such as a positive control, a negative control, a historical
control, a historical norm, or the level of another reference
molecule in the biological sample. In some embodiments, the ratio
of the biomarker and a reference molecule is determined to aid in
the monitoring of the treatment.
Treatments
[0127] In some aspects, the present invention provides a method for
treating a subject diagnosed with gingivitis using one or more of
the biomarkers described herein. For example, in one embodiment,
the method comprises a method of treating a subject composing
detecting that the level of the one or more biomarkers in a saliva
sample of the subject is differentially expressed as compared to
the level in a comparator control, and administering a gingivitis
treatment to the subject. Exemplary treatments administered to the
subject include, but is not limited to administration of a
therapeutic agent, dental procedures, periodontal procedures,
surgical procedures, and communication or training of improved oral
hygiene.
[0128] Exemplary procedures include, but is not limited to,
professional plaque cleaning, scaling, root planning, dental
restoration, curettage, flap surgery, bone and tissue grafts,
guided tissue regeneration, oral irrigation, interdental brushing
and brushing using wooden or plastic pick.
[0129] In some embodiments, treatment comprises administering a
disease-modulating agent to a subject. The agent can be a
therapeutic or prophylactic used in subjects diagnosed or
identified with a disease or at risk of having the disease. For
example, in some embodiments, the therapeutic or prophylactic agent
may be in the form of a toothpaste, mouthwash, dental strips, or
other formulations suitable for delivery to the gums. In some
embodiments, modifying therapy refers to altering the duration,
frequency or intensity of therapy, for example, altering dosage
levels. Exemplary therapeutic or prophylactic agents include, but
is not limited to, antiseptic and antimicrobial agents, such as
triclosan, chlorhexidine, and hydrogen peroxide; plaque reducers;
anti-inflammatory agents, such as thymol, menthol, eucalyptol, and
methyl salicylate; antibiotic agents, such as minocycline and
doxycycline; nonsteroidal anti-inflammatory drugs (NSAIDs);
chlorohexidine rinses; toothpastes containing Stannous, Zinc,
Triclosan, and/or hydrogen peroxide; and mouthwashes containing
Triclosan, Cetylpyridinium chloride, other quats (e.g., BKC) and/or
essential oils.
[0130] In various embodiments, effecting a therapy comprises
causing a subject to or communicating to a subject the need to make
a change in lifestyle, for example, improving oral hygiene, more
frequent flossing, or more frequent brushing of teeth. The therapy
can also include dental procedures, periodontal procedures, or
surgery. Exemplary procedures include, but is not limited to,
professional plaque cleaning, scaling, root planning, dental
restoration, curettage, flap surgery, bone and tissue grafts,
guided tissue regeneration, oral irrigation, interdental brushing
and brushing using wooden or plastic pick.
[0131] Measurement of biomarker levels allow for the course of
treatment of a disease to be monitored. The effectiveness of a
treatment regimen for a disease can be monitored by detecting one
or more biomarkers in an effective amount from samples obtained
from a subject over time and comparing the amount of biomarkers
detected. For example, a first sample can be obtained prior to the
subject receiving treatment and one or more subsequent samples are
taken after or during treatment of the subject. Changes in
biomarker levels across the samples may provide an indication as to
the effectiveness of the therapy.
[0132] To identify therapeutics or drugs that are appropriate for a
specific subject, a test sample from the subject can also be
exposed to a therapeutic agent or a drug, and the level of one or
more biomarkers can be determined. Biomarker levels can be compared
to a sample derived from the subject before and after treatment or
exposure to a therapeutic agent or a drug, or can be compared to
samples derived from one or more subjects who have shown
improvements relative to a disease as a result of such treatment or
exposure. Thus, in one aspect, the invention provides a method of
assessing the efficacy of a therapy with respect to a subject
comprising taking a first measurement of a biomarker panel in a
first sample from the subject; effecting the therapy with respect
to the subject; taking a second measurement of the biomarker panel
in a second sample from the subject and comparing the first and
second measurements to assess the efficacy of the therapy.
[0133] Additionally, therapeutic or prophylactic agents suitable
for administration to a particular subject can be identified by
detecting a biomarker (which may be two or more) in an effective
amount from a sample obtained from a subject and exposing the
subject-derived sample to a test compound that determines the
amount of the biomarker(s) in the subject-derived sample.
Accordingly, treatments or therapeutic regimens for use in subjects
having a disease or subjects at risk for developing a disease can
be selected based on the amounts of biomarkers in samples obtained
from the subjects and compared to a reference value. Two or more
treatments or therapeutic regimens can be evaluated in parallel to
determine which treatment or therapeutic regimen would be the most
efficacious for use in a subject to delay onset, or slow
progression of a disease. In various embodiments, a recommendation
is made on whether to initiate or continue treatment of a
disease.
[0134] In various exemplary embodiments, effecting a therapy
comprises administering a disease-modulating drug to the subject.
The subject may be treated with one or more disease-modulating
drugs until altered levels of the measured biomarkers return to a
baseline value measured in a population not suffering from the
disease, experiencing a less severe stage or form of a disease or
showing improvements in disease biomarkers as a result of treatment
with a disease-modulating drug. Additionally, improvements related
to a changed level of a biomarker or clinical parameter may be the
result of treatment with a disease-modulating drug.
[0135] A number of compounds such as a disease-modulating drug may
be used to treat a subject and to monitor progress using the
methods of the invention. In some embodiments, the
disease-modulating drug comprises antiseptic and antimicrobial
agents, such as triclosan, chlorhexidine, and hydrogen peroxide;
plaque reducers; anti-inflammatory agents, such as thymol, menthol,
eucalyptol, and methyl salicylate; antibiotic agents, such as
minocycline and doxycycline; and nonsteroidal anti-inflammatory
drugs (NSAIDs).
[0136] The beneficial effects of these and other drugs can be
visualized by assessment of clinical and laboratory biomarkers.
[0137] Any drug or combination of drugs disclosed herein may be
administered to a subject to treat a disease. The drugs herein can
be formulated in any number of ways, often according to various
known formulations in the art or as disclosed or referenced
herein.
[0138] In various embodiments, any drug or combination of drugs
disclosed herein is not administered to a subject to treat a
disease. In these embodiments, the practitioner may refrain from
administering the drug or combination of drugs, may recommend that
the subject not be administered the drug or combination of drugs or
may prevent the subject from being administered the drug or
combination of drugs.
[0139] In various embodiments, one or more additional drugs may be
optionally administered in addition to those that are recommended
or have been administered. An additional drug will typically not be
any drug that is not recommended or that should be avoided.
EXAMPLES
[0140] The invention is further described in detail by reference to
the following experimental examples. These examples are provided
for purposes of illustration only, and are not intended to be
limiting unless otherwise specified. Thus, the invention should in
no way be construed as being limited to the following examples, but
rather, should be construed to encompass any and all variations
which become evident as a result of the teaching provided
herein.
[0141] Without further description, it is believed that one of
ordinary skill in the art can, using the preceding description and
the following illustrative examples, make and utilize the present
invention and practice the claimed methods. The following working
examples therefore are not to be construed as limiting in any way
the remainder of the disclosure.
Example 1: Salivary exRNA Biomarkers to Detect Gingivitis and
Monitor Disease Regression
[0142] Extracellular RNAs (exRNAs) are emerging molecular targets
as biomarkers in bodily fluids that can be useful biomarkers for
the disease detection and monitoring. The NIH's Extracellular RNA
Communication Consortium (ERCC) credentialed the existence, the
biology and the translational utilities of exRNA in bodily fluids,
including saliva (Ainsztein et al., 2015, J Extracell Vesicles 4,
27493). The human salivary transcriptome was firstly described in
2004 (Li et al., 2004, J Dent Res, 83, 199-203) followed by the
intense investigations in the following years (Nussbaumer et al.,
2006, Forensic Sci Int, 157, 181-6). Inflammatory mRNA markers can
be detected in whole saliva to monitor the status of periodontal
disease in type II diabetes patients (Gomes et al., 2006, J
Periodontal Res., 41, 177-83). mRNA expression of human beta
defensin-1 and -2 in the gingival tissue are associated with
gingivitis, aggressive and chronic periodontitis. Also, the
expression levels of Toll-like receptors (TRL) TRL7, TRL9,
IFN-alpha1 messenger RNAs (mRNAs) (Kajita et al., 2007, Oral
Microbiol Immunol, 22, 398-402) and MYD88 mRNA (Ghaderi et al.,
2014, J Indian Soc Periodontal., 18, 150-154) were significantly
lower in gingivitis than in periodontitis lesions. In addition,
four miRNAs (hsa-miR-451, hsa-miR-223, hsa-miR-486-5p,
hsa-miR-3917) were significantly overexpressed, and 7
(hsa-miR-1246, hsa-miR-1260, hsa-miR-141, hsa-miR-1260b,
hsa-miR-203, hsa-miR-210, hsa-miR-205) were underexpressed by
>2-fold in gingivitis compared to healthy gingiva
(Stoecklin-Wasmer et al., 2012, J Dent Res., 91, 934-40). However,
not much evidence can be found in the literature about the long
non-coding (lnc) RNAs as biomarkers for periodontal diseases (Wang
et al., 2016, Cell Death Dis., 7, e2327), especially for gingivitis
as it is yet a new and a flourishing field. Bochenek et al.,
reports about the downregulation of large non-coding RNA ANRIL
associated with atherosclerosis, periodontitis and several forms of
cancer (Bochenek et al., 2013, Hum Mol Genet. 22, 4516-27).
[0143] The experiments presented herein were conducted to examine
whether salivary extracellular RNA (exRNA) biomarkers can be
developed for gingivitis detection and monitoring disease
progression or regression. Salivary exRNA biomarker candidates were
developed from a total of 100 gingivitis and non-gingivitis human
participants using Affymetrix's expression microarrays. In the
study design, the diagnosis of gingivitis fulfilled both clinical
and research criteria. The top ten differentially expressed exRNAs
were tested in a clinical cohort to determine if the discovered
salivary exRNA markers for gingivitis were associated with clinical
gingivitis and disease progression/regression. For this purpose,
unstimulated saliva was collected from 30 randomly selected
gingivitis subjects, the gingival and plaque indexes scores were
taken at baseline, 3 & 6 weeks and salivary exRNAs were assayed
by means of quantitative reverse transcription polymerase chain
reaction. It is demonstrated herein that 8 out of 10 salivary exRNA
biomarkers developed for gingivitis were statistically
significantly changed over time, consistent with disease
regression. A panel of four of the eight salivary exRNAs
[NONHSAT006501.2; NONHSAT071649; FAM25A; NM_019060] can detect
gingivitis with a clinical performance of 0.91 AUC (area under the
curve) with 71% sensitivity and 100% specificity. The experiments
described herein demonstrate that salivary exRNA biomarkers for
gingivitis detection have been developed. Their clinical values and
utilities have been demonstrated in a pilot clinical study and are
associated with gingivitis regression. These salivary exRNAs offer
strong potential to be advanced for definitive validation and
clinical laboratory development test (LDT). This study addresses
the unmet clinical need of assessing host factors as a companion
diagnostics to detect gingivitis, which can be treated clinically
or therapeutically to halt disease progress and/or regress to a
healthy periodontium.
[0144] The materials and methods used in these experiments are now
described.
Discovery Phase
[0145] Based on the PRoBE (prospective-specimen-collection and
retrospective-blinded-evaluation) study design (Pepe et al., 2008),
saliva was collected prospectively from 750 human subjects.
Subjects were classified as healthy or gingivitis according to
research and clinical criteria. Research criteria consisted of
evaluation of marginal bleeding index (MBI) and pocket depth (PD)
as follows: 1) Healthy (non-periodontal disease): MBI<5%;
PD<4 mm; 2) Gingivitis: MBI>5%; PD<4 mm. Clinical criteria
were assessed by examination of the entire dentition for six sites
per tooth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual,
mid-lingual, and disto-lingual). In addition, the following
parameters were assessed in a full-mouth evaluation: pocket probing
depths, presence/absence of bleeding upon probing, plaque index and
marginal bleeding index, visual signs of gingival tissue
inflammation and radiographic bone levels. The clinical
classification of a subject's periodontal status (i.e. healthy,
gingivitis) was a cumulative assessment of objective evaluations
and clinical judgment that presents a holistic assessment of a
subject's periodontal status.
[0146] In addition, in order to be included in the study, all
subjects must have had at least 20 teeth and could not have
received periodontal treatment or antibiotic therapy three months
prior to the investigation. The volunteers did not previously
undergo any long-term use of medications affecting periodontal
status such as anti-inflammatory drugs. Subjects were excluded if
they were smokers, possessed a history of metabolic bone diseases,
autoimmune diseases, unstable diabetes or post-menopausal
osteoporosis. Women who were pregnant were not included.
[0147] All saliva samples were treated for the concurrent
stabilization of proteins and RNA by the inclusion of a protease
inhibitor cocktail (aprotinin, PMSF and sodium orthovanadate) and
RNase inhibitor (SUPERase In; Ambion, Austin Tex.) based on a
saliva standard operating procedure (SOP) (Henson et al., 2010).
Salivary exRNA was extracted using the RNeasy Micro Kit (Qiagen)
including DNase I digestion. Samples with good purity QC (OD
260/280 .about.1.8) were profiled using the GeneChip Human
Transcriptome Affymetrix HTA 2.0 expression arrays. The salivary
exRNA biomarker candidates were identified from a discovery cohort
of 50 gingivitis and 50 age/gender-matched control subjects with
healthy periodontium. The top 10 differentially expressed exRNA
biomarker candidates between gingivitis and healthy groups were
advanced for validation by means of quantitative reverse
transcription polymerase chain reaction (qRT-PCR) using an
independent cohort of 30 randomly selected gingivitis subjects in
the pilot clinical research study.
Pilot Clinical Research Study
[0148] Clinical Stage
[0149] For analysis of saliva samples, 30 volunteers (aged 18-65),
diagnosed with gingivitis were included in this study. The duration
of this project was 7 weeks (including 1 week pretrial washout
period) and included treatment of gingivitis by brushing with
toothpastes. The inclusion criteria encompassed: good general
health, presence of >20 natural uncrowned teeth (excluding third
molars), no history of allergy to personal care consumer products,
or their ingredients, initial gingivitis index of at least 1.0 as
determined by the Loe-Silness Gingival Index (GI) (Loe, 1967,
Journal of Periodontology, 38, 610-616) and initial plaque index of
at least 1.5 as determined by the Quigley and Hein Plaque Index
(PI) (Turesky Modification) (Quigley & Hein, 1962, JADA, 65,
26-29; Turesky et al., 1970, J. Periodontol, 41, 41-43). None of
the individuals had a history of any medical condition, which
required pre-medication or the presence of any pocket equal or
deeper than 5 mm (except for 3rd molars). Other exclusion criteria
involved five or more carious lesions, other disease of the hard or
soft oral tissues, impaired salivary function, use of medications
that can currently affect salivary flow or use of antibiotics and
antimicrobial drugs within 30 days prior to the first study visit.
Patients with periodontitis were excluded from the study.
[0150] On a given day each volunteer was subjected to an
examination including measurements of GI and PI at Screening (Scr),
baseline (B), 3 & 6 weeks. In addition, unstimulated saliva
samples were obtained by spitting method at B, 3 & 6 weeks and
immediately frozen at -20.degree. C. until further processing. The
samples were then thawed, centrifuged at 2600 g for 15 minutes at
4.degree. C., and stored at -80.degree. C. until analysis.
[0151] Laboratory Stage
[0152] For the initial validation phase, the direct saliva
transcriptome analysis (DSTA) was performed that uses cell-free
saliva supernatant instead of isolated mRNA for saliva
transcriptomic detection (Lee et al., 2011). In this study, 10
salivary exRNA biomarker candidates for gingivitis, discovered
using the Affymetrix microarray HTA 2.0, were evaluated by reverse
transcription quantitative real-time PCR (RT-qPCR) in 30 gingivitis
samples from the clinical phase at B, 3 & 6 weeks. The qPCR
associated with melting-curve analysis was conducted by the use of
the LightCycler.RTM. 480 Real-Time PCR System by Roche Applied
Science with a fixed thermal-cycling program. All primers used in
RT-qPCR were designed by use of PRIMERS software, and produced by
Sigma after a BLAST search.
[0153] Statistical Analysis
[0154] Kruskal-Wallis tests were used to compare quantitative
markers and chi-squared test to compare categorical markers between
the two groups (healthy and gingivitis) in the discovery phase of
transcriptomic analysis. Statistical comparison by the analysis of
variance (ANOVA) was performed at a significance level of
p<0.05. In addition, the association between exRNA biomarker
changes and initial microarray data was investigated. Afterwards,
the linear regression analysis was used to construct the final
panel of biomarkers with best clinical performance for gingivitis
detection. A paired t-test along with the 95% confidence interval
(CI) was used to compare GI and PI scores over different time
periods. In addition, a generalized estimating equation (GEE)
models were added to show the overall trends across all 3 time
points (B-week 3-week 6). Finally, intra- and interindividual
variability between two different clinical investigators was
examined using the kappa statistic (McHugh et al., 2012, Biochem.
Med. (Zagreb), 22, 276-282).
[0155] The results of the experiments are now described.
HTA Microarray Profiling
[0156] The discovery phase using Affymetrix HTA microarray
profiling on 50 gingivitis and 50 healthy individuals revealed 25
salivary exRNA biomarker candidates that were differentially
expressed between gingivitis and healthy subjects (p<0.05): 4
with increased expression and 21 with decreased expression [1.4-2.9
absolute fold change] (FIG. 1). The top 10 salivary exRNA biomarker
genes were advanced for the validation phase, including 3 lnc RNAs
[NONHSAT006501.2, NONHSAT071649, NONHSAT005224] and 7 mRNAs
[AF156166, AJ420500, NR_003225, NM_001146157, AL832615, NM_003064,
NM_019060].
Validation of 10 Salivary exRNA Biomarker Candidates for Gingivitis
by qRT-PCR.
[0157] FIG. 2 presents the direction of the slopes of the marker
from the generalized estimating equation (GEE) models. Eight out of
10 exRNA biomarkers were significantly increased [NONHSAT071649
(m2), NONHSAT005224 (m3), AF156166 (m5), AJ420500 (m6)] or
decreased [NONHSAT006501.2 (m1), NR_003225 (m4), NM_001146157 (m7),
NM_019060 (m10)] over time (p<0.001). Each of the validated
exRNA target is concordant with the HTA 2.0 microarray data (FIG.
2).
[0158] qRT-PCR results showed similar trends as revealed by the HTA
2.0 Affymetrix array analysis, i.e. NONHSAT006501.2 (m1) showed an
average decrease of 5.59 fold (p<0.001), while NONHSAT071649
(m2) revealed an average increase of 5.54 fold (p<0.001) (FIG.
3). In addition, FIG. 3 presents a plot with fold changes and 95%
confidence intervals (CIs) for each marker on the log base 2 scale
for B, 3 and 6 weeks time point.
Linear Regression Analysis
[0159] The potential clinical discriminatory power of the developed
salivary exRNA for gingivitis detection was evaluated. Linear
regression analysis of 8 validated exRNAs revealed that four exRNA
marker model [NONHSAT006501.2 (m1), NONHSAT071649 (m2),
NM_001146157 (m7), NM_019060 (m10)] could potentially provide a
discriminatory performance of 0.91 AUC (area under the curve) with
71% sensitivity and 100% specificity (FIG. 4).
Clinical Outcomes
[0160] FIG. 5 presents the clinical and demographic data collected
for the 30 subjects (mean age 28.2.+-.7.77, F=17; M=13M), involved
in the validation phase (i.e. subject's age, gender, GI and PI
scores at baseline, after 3 and 6 weeks). Both GI and PI (FIG. 6)
showed significantly decreased scores over time [i.e. GI for B-week
6 (0.001) and PI for B-week 6 (<0.001)] due to good oral hygiene
regimens implemented by brushing with toothpastes. The GI scores
improved for 60% and PI for 93.3% of subjects over the period of 6
weeks.
Assessment of Biomarker Expression Levels Between Groups at Each
Time Point and Longitudinally
[0161] The levels of 8 salivary exRNA biomarkers were measured at
each time point and longitudinally (FIG. 7). All 8 validated exRNA
biomarkers were statistically significantly different over time
(B-week 3 & B-week 6) (GEE p-values<0.001) showing either
increased [NONHSAT071649 (m2), NONHSAT005224 (m3), AF156166 (m5),
AJ420500 (m6)] or decreased trend over time [NONHSAT006501.2 (m1),
NR_003225 (m4), NM_001146157 (m7), NM_019060 (m10)] (FIG. 7).
Investigation of Potential Clinical Evaluators Bias
[0162] The were no significant inter-examiner differences between
the clinical evaluators, except for time point 6 weeks (FIG. 8).
This is despite the fact that all examiners were initially
calibrated.
Differentially Expressed Salivary exRNA Analysis
[0163] The HTA array profiling revealed initially 25 salivary exRNA
biomarker candidates that were differentially expressed between
gingivitis and non-gingivitis healthy subjects (p<0.05) (FIG.
1). Of these, ten were selected as candidate biomarkers for further
validation in the clinical study based on their known association
with inflammation and periodontal diseases as well as p-values
(p<0.05) and the highest absolute fold changes in their
expression levels between gingivitis and control groups with
healthy periodontium. Interestingly, only very few had been
previously reported in bodily fluids, but not in human saliva.
[0164] Eight out of 10 selected salivary exRNAs, initially
validated in the clinical study [3 lnc exRNAs: NONHSAT006501.2
(m1), NONHSAT071649 (m2), NONHSAT005224 (m3) as well as 5 mRNAs:
NR_003225 (m4), AF156166 (m5), AJ420500 (m6), NM_001146157 (m7),
NM_019060 (m10)], showed statistically significant differentially
expressed levels (p<0.05) over time (Baseline-week 3 &
Baseline-6 week) in the same directions as the HTA microarray
discovery data (FIG. 2). Thus, qRT-PCR analysis further supported
microarray discovery findings, however with increase in their
alteration levels compared to the initial data. This change might
be a result of the interindividual variability in exRNA
patterns.
Biomarker Panel for Gingivitis
[0165] The linear regression analysis of the top ranking, initially
validated, salivary exRNA markers revealed that a four exRNA marker
model [NONHSAT006501.2 (m1), NONHSAT071649 (m2), NM_001146157 (m7),
NM_019060 (m10)] could potentially provide a discriminatory
performance of 0.91 AUC with 71% sensitivity and 100% specificity
(FIG. 3).
Description of Potential Functions of Initially Validated exRNAs
for Gingivitis
[0166] Long noncoding RNAs (lncRNAs) have generated widespread
interest in recent years as potentially associated in the induction
of particular diseases or developmental processes, but knowledge of
the particular pathogenetic mechanisms of actions is still limited.
An area of studying lncRNAs, their biology and functions, is still
emerging (Kung et al., 2013, Genetics, 193, 651-669). [0167]
NONHSAT006501.2 (m1) [Gene & mRNA Accession: 573288, Gene
Symbol: SPRR1A, Noncode Gene ID: NONHSAG002962.2,
lnc-SPRR1A-1-1_dup1,lnc-S] is reported as related to epidermatitis
development, keratinocyte differentiation and keratinization (Gibbs
et al., 1993, Genomics, 16, 630-7; Stemmler et al., 2009, Int. J.
Immunogenet., 36, 217-22); [0168] NONHSAT071649 (m2) [Gene
Accession: OTTHUMT00000328143, Gene symbol: AC073046.25,
lnc-TET3-2:1] is a member of the ten-eleven translocation (TET)
gene family, that plays a role in the DNA methylation process
(Langemeijer et al., 2009, Cell Cycle, 8, 4044-8); [0169]
NONHSAT005224 (m3) [Gene Accession: OTTHUMT00000033693, Gene
symbol: RP5-965F6.2] is a new lncRNA and has not been reported yet
in the publications.
[0170] Messenger RNAs (mRNAs) are an emerging target for
noninvasive diagnostic applications. The identification of
saliva-derived mRNA in normal and cancer patients (Li et al., 2004,
J Dent Res, 83, 199-203; Hu et al., 2008, Clin. Chem., 54, 824-832)
and other forensic applications (Juusola et al., 2005, Forensic
Sci. Int., 152, 1-12) have opened up a new avenue for further
clinical usage. [0171] NR_003225 (m4) [Gene Accesion: NR_003225,
Gene symbol: LGALS3] is a non-coding RNA, that encodes a member of
the galectin family of carbohydrate binding proteins that play a
role in apoptosis, innate immunity, neutrophil, eosinophil &
macrophage chemotaxis and negative regulation of endocytosis. It
exhibits antimicrobial activity against bacteria and fungi (Raz et
al., 1991, Cancer Res., 51, 2173-8). It is also associated with
increased risk for rheumatoid arthritis (Atabaki et al., 2017,
Biomed Rep. 6, 251-255). Therefore, in gingivitis, which is an
inflammatory conditions of the gingival tissues, decreased levels
of NR_003225 was observed, both in the initial microarray data and
in qRT-PCR results. [0172] AF156166 (m5) [Gene Accession: AF
156166] is Homo sapiens putative tumor suppressor mRNA. However,
not much information about this specific exRNA can be found in the
literature (Boultwood et al., 2000, Genomics 66, 26-34). [0173]
AJ420500 (m6) [Gene Accession: AJ420500, Gene symbol: SOX4]
functions in the apoptosis pathway leading to cell death as well as
to tumorigenesis, and may mediate downstream effects of parathyroid
hormone (PTH) and PTH-related protein (PTHrP) in bone development.
It is also related to obesity and type 2 diabetes (Ragvin et al.,
2010, Proc Natl Acad Sci USA, 107, 775-80). [0174] NM_001146157
(m7) [Gene Accession: NM_001146157, XM_001723781, XM_002343005,
XM_926530, XM_937048, Gene symbol: FAM25A] when it is
downregulated, it represents an increased risk for inflammation and
infectious disease with a decrease in immune response (Wang et al.,
2014, PLoS One, 9, e92504; Mauritz et al., 2010, J Biomed Opt., 15,
030517; Deloukas et al., 2004, Nature, 429, 375-81). [0175]
NM_019060 (m10) [Gene Accession: NM_019060, Gene symbol: CRCT1].
This mRNA has been recently linked to esophageal cancer (Wu et al.,
2016, Tumour Biol., 37, 8271-9) and oropharyngeal squamous cell
carcinomas (Masterson et al., 2015, Cancer Sci., 106, 1568-75).
However, the underlying mechanism remains still unclear. It
promotes tumor cell apoptosis and upregulates the expression of
apoptosis-related proteins (Wu et al., 2016, Tumour Biol., 37,
8271-9).
[0176] The above-mentioned unique salivary exRNAs can be very
useful in discrimination of patients with gingivitis and with
healthy periodontium as well as in monitoring regression of
gingivitis. The use of saliva transcriptomes can be further
advanced for translational and clinical applications.
[0177] These experiments demonstrate that 8 out of 10 examined
salivary exRNA biomarkers for gingivitis were significantly
increased or decreased over time (baseline to week 3 & baseline
to week 6) in the same directions as based on the independent
discovery sample with a different technological microarray
platform. The four exRNA marker model [NONHSAT006501.2,
NONHSAT071649, NM_001146157, NM_019060] could potentially provide a
discriminatory performance of 0.91 AUC with 71% sensitivity and
100% specificity. Based on clinical outcomes (decrease in GI &
PI), improving over time during these 6 weeks with good oral
hygiene regimen (i.e. brushing with toothpastes), this study
provides good evidence that 8 validated salivary exRNA markers may
be useful in reflecting oral health and can be used to monitor
disease regression over time.
[0178] The disclosures of each and every patent, patent
application, and publication cited herein are hereby incorporated
herein by reference in their entirety. In the event of a conflict
in a definition in the present disclosure and that of a cited
reference, the present disclosure controls. While this invention
has been disclosed with reference to specific embodiments, it is
apparent that other embodiments and variations of this invention
may be devised by others skilled in the art without departing from
the true spirit and scope of the invention. The appended claims are
intended to be construed to include all such embodiments and
equivalent variations.
Sequence CWU 1
1
101317DNAArtificial SequenceSynthetic 1gtaatgtggt ccacagccat
gcccttgagg agctggccac tggatactga acaccctact 60ccattctgct tatgaatccc
atttgcctat tgaccctgca gttagcatgc tgtcaccctg 120aatcataatc
gctcctttgc acctctaaaa agatgtccct taccctcatt ctggagggct
180cctgagcctc tgcgtaaggc tgaacgtctc actgactgag ctagtcttct
tgttgctcgg 240gtgcatttga ggatggattt ggggaaggat caagtgaacc
atccctagtc ttccttcaat 300aaataacttt taactcc 3172390DNAArtificial
SequenceSynthetic 2cgctccgccc cggaggcggc gggcaggcag cactgccttc
tccagcgtcc agaccctgga 60ggaaaaatac caggagaaac tgctcactca gctctgcccc
caccacaccc ctacctgctc 120aactcatgcc tgggtccagg gtgggtgagg
gtgaagaacc caccgggcca agatgatccc 180ttttctgagg gctgctgctg
gtgtcctccc ccagatcctg ggccccagca ggtgggagag 240tggcccccta
cggagtccga tcagactgct gcagaggagg tgaagagggg ttgagaagag
300gcatccatcc acgagactga agccacttgc cttcaccctt gtagactctt
gactgttcta 360ggcgagaagg acctgttggt ggcctttgga 3903547DNAArtificial
SequenceSynthetic 3tttctcagcc tggagactga aagctctctt tggctgttgg
ccctcccagg cagagtccac 60tggctgttag ggtgaaatgg ggctgatgct tcctggaatc
caccagaagt atgcaaattg 120caccatctct ttcagctgcc tgcgcctgca
ttccatcgag gattccggct cgtcccccag 180tggcaacaac tagagaggag
gtgaggatcc ccggcgctgc catctgatag gctgtctccc 240tagctcctct
tgcactggca atcctttcat cacacaggcc ttgttttgaa gggacctatt
300ccacccacag tcgtttctca cctctaggag gccaaaaagc tgtagtcatt
gctgtggtat 360caggaactcg agttcctctc agaggtgttg tgaagagctt
cccttccaac agtacatggc 420ctaaatacca gggaggaagt ttctgacttt
ttccatcttc agtaaaacag aacctctgtt 480gtggatgcag tggctttgca
aggagagtgg cattgtctct tggtgaatgt agttgttcaa 540gtcatgg
54741973DNAArtificial SequenceSynthetic 4gtgtgcaaat agaggaataa
atagcagggc agcaactatg tctggaggtc attgtctttc 60ctgtctcagt agtaatcaat
cactgcttat cttcaaaaac ccagagtagg ggatggggca 120gttagtgggg
acagagggca gatgggtaag attcagagca caggctagtg tgacggaagt
180ttaaacttgt gagttaaata gggtttggca atctagctgg atagcatccc
tgccccttga 240agagatgttt ttgtggcgcc acactactga cttaggcata
atgcctagag atggattaga 300actgcacaat gaactagtgg tgaggttcag
tttaatggaa attggtgaaa gcttttagga 360taaaatgata atctttgttt
ctttcaggaa aatggcagac aatttttcgg taagtgtttt 420atgcctgttt
cttccccttg atcagctcca catggttgag ggttgggggt tttgttttta
480ccatgacttt cccttttcac tctcccactg cgtggcttcc cctggactca
tttgtccaat 540gagggcttgc aagctggagc cttgtttttc cagcagcaga
tttgggaaga aagccaggca 600gagcgaggcc tgggactcac tcacagtaac
cctttcacca aaaggcccag ggcggaaggg 660agtggactct gccggcagga
gctgagaaat cctctgagta gcgggaagtg cggtacagtc 720tgggcattct
gatgtttgtg attgtttttc tcacggtgat gaaaaagtat gtgctataag
780tagaggagcg ctaactcctg acttgagcta attatgaaaa tgcagccctc
cctgatctga 840gacgttggga ggcaagaata aagtgaaaaa gtatatgtaa
tcccaacatc taattttagt 900cttagaaact caaactatta ataagtggaa
aaagtttaat gatatgcatg taatgccttt 960gccatattcc tctccttctt
agatcacata ttcctatttt cctgaaaatt ctgcttttga 1020gaatgctttc
tgtcccgtaa ttgtgtatgt ctttctttcc agctccatga tgcgttatct
1080gggtctggaa acccaaaccc tcaaggatgg cctggcgcat gggggaacca
gcctgctggg 1140gcagggggct acccaggggc ttcctatcct ggggcctacc
ccgggcaggc acccccaggg 1200gcttatcctg gacaggcacc tccaggcgcc
taccctggag cacctggagc ttatcccgga 1260gcacctgcac ctggagtcta
cccagggcca cccagcggcc ctggggccta cccatcttct 1320ggacagccaa
gtgccaccgg agcctaccct gccactggcc cctatggcgc ccctgctggg
1380ccactgattg tgccttataa cctgcctttg cctgggggag tggtgcctcg
catgctgata 1440acaattctgg gcacggtgaa gcccaatgca aacagaattg
ctttagattt ccaaagaggg 1500aatgatgttg ccttccactt taacccacgc
ttcaatgaga acaacaggag agtcattgtt 1560tgcaatacaa agctggataa
taactgggga agggaagaaa gacagtcggt tttcccattt 1620gaaagtggga
aaccattcaa aatacaagta ctggttgaac ctgaccactt caaggttgca
1680gtgaatgatg ctcacttgtt gcagtacaat catcgggtta aaaaactcaa
tgaaatcagc 1740aaactgggaa tttctggtga catagacctc accagtgctt
catataccat gatataatct 1800gaaaggggca gattaaaaaa aaaaaaagaa
tctaaacctt acatgtgtaa aggtttcatg 1860ttcactgtga gtgaaaattt
ttacattcat caatatccct cttgtaagtc atctacttaa 1920taaatattac
agtgaattac ctgtctcaat atgtcaaaaa aaaaaaaaaa aaa
19735722DNAArtificial SequenceSynthetic 5gagactgcat agggctcggc
gtggatcttg ttaatgctga ttctggtaca gtaggtctag 60ggcggggcct gagattctgc
atttctaaca agaacccagg tgatgctgac gctgctgggc 120caaaaaagac
actttgagta gcaagggtta ggcaaccttt aaagggccct tcaagagtct
180aagattccat gaaggatact atttcctcta caagcttgtg aaagtcttcc
agtgctactg 240ggaatggggt acagggataa atctcactgt tttgacctca
cagaagtaaa cccctagaat 300catgttctca aaatgaaaca ctggattgct
gaactgatgg cattgagaat taaggctcca 360aaatcctggg agtttcatac
ctaactccac tgcctttgcc ttatgatgca cactgctccc 420tctatccctc
cctcccaggg tctgcagaga tgaactatgc tgttttaggt ctcattggtc
480cttatacctt ccctaaacca ggaggacttt ggagcctgct gacacaggga
gttctacatg 540tctaagcacg cagctgctag agtcctcagc catctgagct
aaatagctgc tcagagacaa 600ttagtacacc tccgtatytt acagataaag
gaactgaagt ccaaacaagc caagctaccc 660aaccaaggct cacagcaggc
aagaggataa aaaccatgtc ctttgactcc caggttagtt 720tt
72261233DNAArtificial SequenceSynthetic 6ccacgcgtcc gcatattttt
tcttttgtcc ctttttttct ttcctttctt tttacttcct 60ttatttcttt attccttcct
tttccttttt ttcttttttt tttctttttt tttttttttt 120ggtagttgtt
gttacccacg ccattttacg tctccttcac tgaagggcta gagttttaac
180ttttaatttt ttatatttaa atgtagactt ttgacacttt taaaaaacaa
aaaaagacaa 240gagagatgaa aacgtttgat tattttctca gtgtattttt
gtaaaaaata tataaagggg 300gtgttaatcg gtgtaaatcg ctgtttggat
ttcctgattt tataacaggg cggctggtta 360atatctcaca cagtttaaaa
aatcagcccc taatttctcc atgtttacac ttcaatctgc 420aggcttctta
aagtgacagt atcccttaac ctgccaccag tgtccaccct ccggcccccg
480tcttgtaaaa aggggaggag aattagccaa acactgtaag cttttaagaa
aaacaaagtt 540ttaaacgaaa tactgctctg tccagaggct ttaaaactgg
tgcaattaca gcaaaaaggg 600attctgtagc tttaacttgt aaaccacatc
ttttttgcac tttttttata agcaaaaacg 660tgccgtttaa accactggat
ctatctaaat gccgatttga gttcgcgaca ctatgtactg 720cgtttttcat
tcttgtattt gactatttaa tcctttctac ttgtcgctaa atataattgt
780tttagtctta tggcatgatg atagcatatg tgttcaggtt tatagctgtt
gtgtttaaaa 840attgaaaaaa gtggaaaaca tctttgtaca tttaagtctg
tattataata agcaaaaaga 900ttgtgtgtat gtatgtttaa tataacatga
caggcactag gacgtctgcc tttttaaggc 960agttccgtta agggtttttg
tttttaaact tttttttgcc atccatcctg tgcaatatgc 1020cgtgtagaat
atttgtctta aaattcaagg ccacaaaaac aatgtttggg ggaaaaaaaa
1080gaaaaaatca tgccagctaa tcatgtcaag ttcactgcct gtcagattgt
tgatatatac 1140cttctgtaaa taactttttt tgagaaggaa ataaaatcag
ctggaactga accctaaaaa 1200aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa agg
12337362DNAArtificial SequenceSynthetic 7tcagcatcct agttcaccac
tgtctgctgc cacacgatgc tgggaggcct ggggaagctg 60gctgccgaag gcctggccca
ccgcaccgag aaggccaccg agggagccat tcatgccgtg 120gaagaagtgg
tgaaggaggt ggtgggacac gccaaggaga ctggagagaa agccattgct
180gaagccataa agaaagccca agagtcaggg gacaaaaaga tgaaggaaat
cactgagaca 240gtgaccaaca cagtcacaaa tgccatcacc catgcagcag
agagtctgga caaacttgga 300cagtgagtgc acctgctacc acggcccttc
cccagtctca ataaaaagcc atgacatgtg 360ta 36284471DNAArtificial
SequenceSynthetic 8gtggctcttg agcatgggtg ggggaagccc ccacatatct
gagtcagtgc cacctggaca 60ctacccttgg agcatcctgc tgaggtggcc attcaggttt
tctttccttt ccttttattc 120cactgtttgc ctcggacatg aaacatctca
cagactgcct ggaagaaggt ggagcagact 180ggggttaatg gtcagcagca
gcagcatccc caccactggg gctatccctt tttaggccct 240taccatgggc
caaacactga gccgtgtgct tcgtgtaact tctaagcacg cttacctgat
300agagtgccag caaagactca aagaggtgcc tgggcttggc acatagtagc
tattgctact 360attatgaatg ttgttttgtc tttgtttttg ttttgagaca
gggcctcact ctgttgccca 420ggttggagta cagcagtgcc atcatggctc
actgaggcct caacctccct gggtttgggc 480agtcctcccg cctcggcctc
ccgagtggct gggactacag gtgtgcgcca ccaagcccgg 540ccggtttttt
gtattttcag tagagactgg ttttgccaag tcgcccaggc tggtttcgaa
600ctctgtgatc ccagcacttt gggaggccga ggcgggtgga tcatgaggtc
aggagatcga 660gaccatcctg gctaacaagg tgaagccccg tctctactga
aaatacaaaa aattggccgg 720gcgcggtggc gggcgcctgt ggtcccagct
gctcgggagg ctgaggcggg agaatggcgt 780gaacccggga agcggagctt
gcagtgagcc gagattgcgc cactgcggtc cgcagtccag 840cctgggcgac
agagcgagac tctgtctcaa aaaaaaaaaa aaaaaaaaaa aatgccaagc
900tcacccagaa ataaccccgt gcatatatgg tcaacagatc tttgacaagg
ccatcaagga 960tatacaatgt agattctttt attcctttac tttcttaata
gacttgcttt cactgtactg 1020taaaaaaaaa aaaggcacaa tgtagaaagg
aaactctctt caatgaatgg tgttggggaa 1080agtgcatgaa aaagaatgaa
attgcacact tgttttacat catatacaga aaattagctc 1140aaagtggatt
aaagatttaa atgtaatatc tgaaaccatg taaatcctgg aagtaaacat
1200agggaaaaat ctcctcgaca ttggtcataa ttggcaatat tttttttgat
gtaacaccaa 1260agcacaggca acaaaagtga aaataaataa atgggactac
atcaatctta aaaggtttta 1320cacagcaaag gaaaccatga caaaatgaaa
aggcaaccta cgggatggaa gaaaatattt 1380gcgacccata tatttgataa
ggggttattt gaaaaaatat aaggaattca cacaattcaa 1440tagcaaaaat
taataaatac atgaataacg caattaaaaa taggcaaagg accccaatgg
1500acttttttcc ccaaggaaga tatacaaatg gccagccagc atatgaaaag
gtgctcaaca 1560ccactaatca tcagagaaat gcaaatcaaa accacagtga
gatattgcct catagggtag 1620gatggctctt ataaaaaaac gacaagagat
aacaagtgtt ggcgaaagca tagaggaaag 1680agaacccttg tacactgttg
gttggaatgt aaagtggtat aacctttaca gaaaacagta 1740tggaggttcc
tcaaaaaatt agaagcagaa ctaccatacg attcagcaat caggttagaa
1800ccttgaagag agatctgcgc cccatgttta ttacaacact attcacaata
cccaagatat 1860ggaaacagcc taagtgtcca gcaacagatg aatggataaa
taaaatacat ataaacaatg 1920gactattagc cattcaaaag aagaaactcc
tgtcctggat aaacctggag gacattacgc 1980taagtgaaat aagccagaca
ccgaaagaca agttttgtat gatctcactt atatgtggga 2040tctaagagag
tcaaactcat aaaaacagat agtagaatgg tggttgccaa gggctggagg
2100tggggaaaat gggaagctat taatcaaagg gtgtaaactt tcagttataa
gatgaacaaa 2160ttctggagat ttaatgtaca gcataggtgg taatggatgt
aataaatttg attgtgataa 2220ttagtacaca atatatacat atatgaaatc
atcacattgt atgcattaaa tatacacaat 2280ccttgtcaac tcaatatttt
taaaaaaatg tttaaaatgc ctaggtcata agaattctga 2340gaatgaaata
caacaacata catgaatgga cctgctacac agaaggtgct aaataggttt
2400gttttgtttt attttatttc aactctggca gatgtagacc tattgggaaa
gaatatagaa 2460tgcacttgtg cacaaggatt atctatacga tggttaaata
tcctgcatac atgccatgtc 2520atttctactc ctcagtcaat ggataataaa
agcagaacca gccttctggt ggtcacaaaa 2580cattttgaca tgagaaaggc
tgatcatgag caatctggca atgtacatcc cagagcgtgc 2640atgccctttg
acccacagct accatgatgt catgtctagc aattagtcct aaggagatga
2700tcagagatgt gtaaagagat ttcattctaa cagcatcctc tgtagtggta
tatgtcaggg 2760gctggtaagc catgtccaga ggagcaggct gcatctggtc
caccacctgt ttttgtaaag 2820tttatcagaa cacagtcatg cccattcatt
tacaaattgt gtatggcttc tttccctgca 2880acagcagagt tgagtgttgc
aacagaaacc tatggcctgc agagtttaaa atatctaccc 2940tttggccttt
tataaaaaaa gtttactgat tcctggtgag tatattaaaa agttaggaaa
3000acctaaatct tccagagtgg agaattagaa agtaagacgt gttgtatata
agacagacag 3060tttgtgtgtg cgtttattta taaatatatt attttgaaat
aatgttgtcg acatatgttg 3120caggtcttaa aaattggtca atatatagtg
ttaatcaaaa aatggcaaat tgtaaaatgt 3180agacagaatg tgattgtgta
ttttgtgcat acaccaacag aaaagggtgc taggaaacct 3240gtggaccaac
atactaagtg tggctctttt gatggtggta tcatggattt ttaaaaatct
3300tcttggtttt ctgtagattc tgactttcct gtaatgagta tgaataagta
tgtatttctt 3360gagaaatgag aaaataactt tatcttccca gatttctcat
aattgaaaat gttggaataa 3420atggtcctgg gacagatctt tccattgaga
agggcggaag ggaaaccctg gggattcagc 3480tgggtttctg ttgcatttct
ggtaacacac agttgtgaaa agccagtgtt ggccattccc 3540caggacagtc
tggggtagag gaggtcagga tttaactact tgagggtccg gggaacagat
3600gtggccacag tccttcctga ctcactgttt tcccttccac agtccccgtc
ttctcttcac 3660tgatgcacat agatgcctga ccagaggaga gatttagttt
tcgtccaagg attatctgtt 3720atgttgcagt tctgaaattc ccataacgtt
taggctagaa cacaagtgat ttcattatct 3780ccaatgtgta tggcttgata
gaaatagatt ccattatgta gcaccttaaa tccagataaa 3840acataaggaa
tttctattcc atgtttgtat gatcaatgtt aataatctaa gaaaatctaa
3900aaagaagcta cttcctctat tacagtatga aataaatatg ctgaatgatt
tgtcttgggg 3960ggtggaatgg aaaggtataa gactgaggag ggtgcctgtg
ggaacagtga taggaatcct 4020ttcttaaggg ttgggtttta catacgtctt
ttaaaataga tgatatcatt aataaattat 4080ctgtgggcat catgaaaaaa
gtgtataacg tacaacttta tgagcttgac agttggtgaa 4140aacttttctg
tttaaaattt tatttggccc tccccaaaag aaatgtttat ttatgagtat
4200taggatagtt ccagcagtaa tgcctcaaaa gaaccaggag gtatagtgtt
gtctaaaatg 4260tggactcagg agccagactg cctggctgtg caactagcct
tgtcacttcc tagatatgtg 4320gcaagttaat taacttctca gtgttcttat
ctgtagaatg gggataatcc taatatacat 4380ctcagggtta tattacaaat
ttgagaagtt aattttgtaa aggacttaga atgatatctg 4440gcaaataaaa
gtgttcataa aagcaaaaaa a 44719598DNAArtificial SequenceSynthetic
9cagagtcact cctgccttca ccatgaagtc cagcggcctc ttccccttcc tggtgctgct
60tgccctggga actctggcac cttgggctgt ggaaggctct ggaaagtcct tcaaagctgg
120agtctgtcct cctaagaaat ctgcccagtg ccttagatac aagaaacctg
agtgccagag 180tgactggcag tgtccaggga agaagagatg ttgtcctgac
acttgtggca tcaaatgcct 240ggatcctgtt gacaccccaa acccaacaag
gaggaagcct gggaagtgcc cagtgactta 300tggccaatgt ttgatgctta
acccccccaa tttctgtgag atggatggcc agtgcaagcg 360tgacttgaag
tgttgcatgg gcatgtgtgg gaaatcctgc gtttcccctg tgaaagcttg
420attcctgcca tatggaggag gctctggagt cctgctctgt gtggtccagg
tcctttccac 480cctgagactt ggctccacca ctgatatcct cctttgggga
aaggcttggc acacagcagg 540ctttcaagaa gtgccagttg atcaatgaat
aaataaacga gcctatttct ctttgcac 59810699DNAArtificial
SequenceSynthetic 10gcccattcca gttggagaac gtagtgagtc tttcagtgga
gccagggtct ggtttgtcgt 60gaggagctcc gcgatgtcct ctcaacagag cgccgtttcc
gccaaaggct tttccaaggg 120gtcgtcccag ggccccgctc cgtgtcccgc
cccggcgccc accccggcgc ccgcctcctc 180ctcctcctgc tgcggctccg
gcaggggctg ctgcggcgac tcaggctgct gcggctccag 240ctccaccagt
tgctgctgct tcccaaggag acgccgccga cagcggagta gtggttgctg
300ctgctgcggg ggcggcagcc agaggtccca gcgctccaac aaccggagct
caggatgctg 360ctccggctgc tgagaggccc gcaaccccca gcgctgcgct
agagaaaccc gcccagccca 420gagcgggccc gccccgctgc ggctcccacg
cggggctggg cctcggagtt tgccccgtaa 480agcgaattgc actttgatgt
tcagaaaccc actttgttct cagccacgca aaactccctg 540accccgatgt
gatttttctc cccggggatt cgagagccat gcgtgggaca ctggacccta
600ctgtctacac gggcttgcac acagcaggtg ctcagcaaat gtctattgat
ttgattgtct 660tttgaagatg tcataataaa gcttctacct cctgaaaaa 699
* * * * *